{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Injectable CJC-1295 combined with ipamorelin improves physical recovery in adults without diagnosed growth-hormone deficiency.", "entry_form": "claim", "gradeable_restatement": "Injectable CJC-1295 combined with ipamorelin improves physical recovery in adults without diagnosed growth-hormone deficiency.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Baseline adult age and absence of diagnosed GH deficiency, exact molecule identity, route, composition, comparator and 4–24-week clinical horizon", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ] }, "hypothesis": { "name": "Injectable Peptide Stacks and Human Recovery", "central_claim": "Injectable CJC-1295 combined with ipamorelin improves physical recovery in adults without diagnosed growth-hormone deficiency.", "proposed_mechanism": "Injectable CJC-1295 combined with ipamorelin improves physical recovery in adults without diagnosed growth-hormone deficiency.", "claimed_scope": "Adults without diagnosed growth-hormone deficiency; a formulation-defined injectable CJC-1295 plus ipamorelin combination; physical recovery over 4–24 weeks", "claimed_level": [ "response" ], "is_conjunctive": false, "conjunctive_note": "The declared clinical causal proposition is represented by SC2. Target engagement, superiority, mechanism, generalization and benefit-harm companions are separately reported and do not substitute for this primary claim." }, "rubric_routing": { "primary_rubric": "06-metabolism-aging.md", "secondary_rubrics": [], "index_notes_applied": [ "The declared clinical causal proposition is represented by SC2. Target engagement, superiority, mechanism, generalization and benefit-harm companions are separately reported and do not substitute for this primary claim." ], "rubric_fit_note": "The frozen framework has no dedicated sports-recovery rubric. Rubric 06 is the nearest metabolism/aging fit. Its unchanged literal Δ criterion concerns lifespan/healthspan; a declared clinical adaptation requires a positive controlled functional, return-to-activity or healing endpoint for the exact intervention and registered population. Endocrine markers, tracer synthesis, lean mass alone and cell migration do not substitute. This adaptation never treats a null test or another molecule as a nominal positive threshold crossing." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "CJC-1295 and ipamorelin stimulate the intended growth-hormone axis in humans.", "subclaim_type": "mechanism", "scope": "Adults without diagnosed growth-hormone deficiency; exact molecule and exposure fixed", "claimed_scope": "Adults without diagnosed growth-hormone deficiency; exact molecule and exposure fixed", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Controlled endocrine pharmacodynamic experiments", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Controlled human CJC-1295 and ipamorelin reports establish single-agent GH-axis activity. For the recovery mechanism, these are endocrine biomarkers; the exact combination has no verified human functional result in this search. The biomarker cap is applied to inference from target engagement to recovery, not a denial that pharmacodynamic stimulation occurred.", "rubric_adaptation": "Clinical recovery adaptation: retain the exact frozen rubric and caps; require positive controlled patient-relevant function or healing for the registered intervention/population. GH and IGF-I changes are target engagement only." }, { "id": "SC2", "statement": "The CJC-1295 plus ipamorelin combination improves physical recovery compared with a credible control.", "subclaim_type": "sufficiency", "scope": "Adults without diagnosed growth-hormone deficiency; physical function, return to activity or healing outcomes over 4-24 weeks", "claimed_scope": "Adults without diagnosed growth-hormone deficiency; physical function, return to activity or healing outcomes over 4-24 weeks", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Controlled combination trials with functional endpoints", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Partial biological support comes from single-agent human pharmacodynamics and related repair experiments. No examined report directly demonstrates a positive functional recovery effect of the exact CJC-1295 plus ipamorelin combination in the registered population. Different hormones, molecules, disease indications and animal injuries do not cross its clinical Δ threshold.", "rubric_adaptation": "Clinical recovery adaptation: retain the exact frozen rubric and caps; require positive controlled patient-relevant function or healing for the registered intervention/population. GH and IGF-I changes are target engagement only." }, { "id": "SC3", "statement": "Evidence for individual peptides establishes the clinical benefit of marketed peptide stacks.", "subclaim_type": "generalization", "scope": "Exact combination, route and composition defined before outcomes", "claimed_scope": "Exact combination, route and composition defined before outcomes", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Direct combination and component-dismantling tests", "hsef_level": "Α", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "The claim that component evidence establishes all marketed stack benefits remains an unsupported generalization. The new BPC-157/TB-500 four-arm rat study supplies a useful counterexample to automatic additivity, while its own positive single-agent mechanical result retains its rat scope. Approved or studied single-agent indications remain distinct.", "rubric_adaptation": "Clinical recovery adaptation: retain the exact frozen rubric and caps; require positive controlled patient-relevant function or healing for the registered intervention/population. GH and IGF-I changes are target engagement only." }, { "id": "SC4", "statement": "The proposed stack has an established net clinical benefit across the promoted healthy-adult uses.", "subclaim_type": "generalization", "scope": "Baseline health status, formulation, adverse events and functional benefit measured together", "claimed_scope": "Baseline health status, formulation, adverse events and functional benefit measured together", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Controlled benefit-harm comparisons", "hsef_level": "Α", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "A broad net-benefit claim across promoted healthy-adult uses has no verified exact-stack controlled benefit-harm comparison. Short CJC tolerability, ipamorelin ileus monitoring, GH-axis metabolic risks and sampled product-identity problems cannot be combined into a measured exact-stack net benefit or universal toxicity conclusion.", "rubric_adaptation": "Clinical recovery adaptation: retain the exact frozen rubric and caps; require positive controlled patient-relevant function or healing for the registered intervention/population. GH and IGF-I changes are target engagement only." } ], "aggregation_rule": "primary-subclaim", "aggregation_preregistered": true, "aggregation_rationale": "The declared clinical causal proposition is represented by SC2. Target engagement, superiority, mechanism, generalization and benefit-harm companions are separately reported and do not substitute for this primary claim.", "primary_subclaim_id": "SC2", "aggregation_derivation": "The preregistered primary-subclaim rule returns SC2 Γ: mechanistic plausibility and partial system support are present, but an exact-combination positive clinical recovery experiment is missing. This is an unproven benefit claim, not a claim that every peptide is ineffective or that future recovery benefit is impossible. Fifty-plus examined originals are mostly component, mechanism, comparator and indication-boundary reports, not fifty trials of the marketed combination.", "aggregation_alternatives": { "weakest_link_would_return": "Α", "primary_subclaim_would_return": "Γ", "scope_matched_would_return": "Γ", "note": "Separate narrow successes do not replace the preregistered full-scope gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M3", "is_nominal": false, "name": "Indication-specific single-agent effects do not transfer to stacks", "core_claim": "GH-axis therapies can improve selected clinical function in predefined disease or functional-limitation settings while exact healthy-adult stacks remain untested.", "explains_what_nominal_does_not": "GH-axis therapies can improve selected clinical function in predefined disease or functional-limitation settings while exact healthy-adult stacks remain untested.", "strongest_supporting_evidence": [ "Controlled hip-replacement GH results PMID12519419 and capromorelin functional-limitation results PMID19174493 show that the entire axis is not clinically inert." ], "strongest_contradictory_evidence": [ "Healthy older MK-677 function was null, pediatric burn safety cannot transfer to critically ill adults, and no exact-stack trial was examined." ], "hsef_level_for_this_model": "Ε", "rationale": "Controlled hip-replacement GH results PMID12519419 and capromorelin functional-limitation results PMID19174493 show that the entire axis is not clinically inert. Healthy older MK-677 function was null, pediatric burn safety cannot transfer to critically ill adults, and no exact-stack trial was examined." }, { "rank_in_tournament": 2, "model_id": "M2", "is_nominal": false, "name": "Endocrine engagement without established functional recovery", "core_claim": "Hormones and composition can change while useful function remains unestablished or unchanged.", "explains_what_nominal_does_not": "Hormones and composition can change while useful function remains unestablished or unchanged.", "strongest_supporting_evidence": [ "The CJC pharmacodynamic reports and MK-677 trial PMID18981485 directly separate engagement/mass from measured function; ROMANA PMID26906526 gives another mass-handgrip dissociation." ], "strongest_contradictory_evidence": [ "Selected capromorelin and hip-replacement functional positives prevent a universal claim that axis engagement can never help; biomarker-only evidence cannot prove a complete clinical mechanism." ], "hsef_level_for_this_model": "Γ", "rationale": "The CJC pharmacodynamic reports and MK-677 trial PMID18981485 directly separate engagement/mass from measured function; ROMANA PMID26906526 gives another mass-handgrip dissociation. Selected capromorelin and hip-replacement functional positives prevent a universal claim that axis engagement can never help; biomarker-only evidence cannot prove a complete clinical mechanism." }, { "rank_in_tournament": 3, "model_id": "M4", "is_nominal": false, "name": "Concurrent rehabilitation and measurement effects", "core_claim": "Apparent recovery can reflect rehabilitation, practice, fluid-related mass or expectation rather than the exact stack.", "explains_what_nominal_does_not": "Apparent recovery can reflect rehabilitation, practice, fluid-related mass or expectation rather than the exact stack.", "strongest_supporting_evidence": [ "Controlled identical-training GH-versus-placebo trials PMID1550219 and 7864103 show gains in both arms without an added GH strength effect. The athlete trial PMID20439575 identifies substantial extracellular-water contributions to lean mass." ], "strongest_contradictory_evidence": [ "These designs do not independently randomize expectation or rehabilitation absence, and GH sprint capacity plus indication-specific function can improve. The exact stack remains untested." ], "hsef_level_for_this_model": "Γ", "rationale": "Controlled identical-training GH-versus-placebo trials PMID1550219 and 7864103 show gains in both arms without an added GH strength effect. The athlete trial PMID20439575 identifies substantial extracellular-water contributions to lean mass. These designs do not independently randomize expectation or rehabilitation absence, and GH sprint capacity plus indication-specific function can improve. The exact stack remains untested." }, { "rank_in_tournament": 4, "model_id": "M1", "is_nominal": true, "name": "Stack-specific recovery benefit", "core_claim": "Exact CJC-1295 plus ipamorelin improves clinical physical recovery in adults without diagnosed GH deficiency.", "explains_what_nominal_does_not": "Exact CJC-1295 plus ipamorelin improves clinical physical recovery in adults without diagnosed GH deficiency.", "strongest_supporting_evidence": [ "Human single-agent GH stimulation and adjacent injury experiments make the mechanism plausible." ], "strongest_contradictory_evidence": [ "No examined exact-combination human functional trial; a mechanistic analogy cannot establish recovery, component additivity or net benefit." ], "hsef_level_for_this_model": "Γ", "rationale": "Human single-agent GH stimulation and adjacent injury experiments make the mechanism plausible. No examined exact-combination human functional trial; a mechanistic analogy cannot establish recovery, component additivity or net benefit." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. PMID12519419 is a placebo-controlled indication-specific positive walking result, while PMID18981485 directly shows GH/IGF-I and mass improvement without functional improvement in healthy older adults. Together they distinguish context-dependent single-agent benefit from both universal axis ineffectiveness and unsupported exact-stack transfer.", "study_separating_rank1_from_rank2": "PMID12519419 is a placebo-controlled indication-specific positive walking result, while PMID18981485 directly shows GH/IGF-I and mass improvement without functional improvement in healthy older adults. Together they distinguish context-dependent single-agent benefit from both universal axis ineffectiveness and unsupported exact-stack transfer.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "16352683", "title": "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.", "citation": "Teichman SL, Neale A, Lawrence B et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism. 2006.", "doi": "10.1210/jc.2005-1536", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16352683/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16352683", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "CJC-1295 alone increased GH and IGF-I for days in two placebo-controlled ascending-dose trials in healthy adults; no serious adverse reactions were reported over 28-49 days.", "what_it_does_not_show": "No combined ipamorelin arm or functional recovery endpoint was measured; short monitored tolerability does not establish chronic stack benefit or safety.", "confounders_present": [ "No combined ipamorelin arm or functional recovery endpoint was measured; short monitored tolerability does not establish chronic stack benefit or safety." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "One report describes two ascending-dose experiments; do not call two published reports two causal classes." ] }, { "n": 2, "pmid": "17018654", "title": "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.", "citation": "Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism. 2006.", "doi": "10.1210/jc.2006-1702", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17018654/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17018654/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "CJC-pulsatility-cohort", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "CJC-1295 in healthy men increased trough and mean GH and IGF-I while preserving pulsatility after one week.", "what_it_does_not_show": "Endocrine dynamics are target engagement rather than recovery; no exact combination or functional comparison was tested.", "confounders_present": [ "Endocrine dynamics are target engagement rather than recovery; no exact combination or functional comparison was tested." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 3, "pmid": "25331030", "title": "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.", "citation": "Beck DE, Sweeney WB, McCarter MD et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease. 2014.", "doi": "10.1007/s00384-014-2030-8", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/25331030/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25331030/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25331030", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "A blinded placebo-controlled phase 2 intravenous ipamorelin study randomized 117 bowel-resection patients; the key meal-tolerance endpoint and secondary efficacy analyses showed no significant differences.", "what_it_does_not_show": "Postoperative ileus, intravenous single-agent dosing and seven-day exposure differ from healthy-adult injectable stacks; nonsignificance does not prove exact equality or refute all doses.", "confounders_present": [ "Postoperative ileus, intravenous single-agent dosing and seven-day exposure differ from healthy-adult injectable stacks; nonsignificance does not prove exact equality or refute all doses." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 4, "pmid": "10496658", "title": "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.", "citation": "Gobburu JV, Agersø H, Jusko WJ et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research. 1999.", "doi": "10.1023/a:1018955126402", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10496658/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10496658/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10496658", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Dose-escalation intravenous ipamorelin in healthy male volunteers produced a single GH episode and supported a pharmacokinetic-pharmacodynamic model.", "what_it_does_not_show": "A hormone response and modeled potency do not show physical recovery, combination efficacy or chronic subcutaneous safety.", "confounders_present": [ "A hormone response and modeled potency do not show physical recovery, combination efficacy or chronic subcutaneous safety." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 5, "pmid": "25042765", "title": "Thymosin β4 administration enhances fracture healing in mice.", "citation": "Brady RD, Grills BL, Schuijers JA et al. Thymosin β4 administration enhances fracture healing in mice. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2014.", "doi": "10.1002/jor.22686", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/25042765/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25042765/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25042765", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Intraperitoneal full-length thymosin beta 4 increased fracture-callus force to failure and stiffness after fibular osteotomy in mice.", "what_it_does_not_show": "This is another molecule in one injury model and species; TB-500 product equivalence and CJC-ipamorelin recovery are not established.", "confounders_present": [ "This is another molecule in one injury model and species; TB-500 product equivalence and CJC-ipamorelin recovery are not established." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 6, "pmid": "20536470", "title": "The effect of thymosin treatment of venous ulcers.", "citation": "Guarnera G, DeRosa A, Camerini R et al. The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences. 2010.", "doi": "10.1111/j.1749-6632.2010.05490.x", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20536470/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20536470/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20536470", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A blinded dose-escalation trial randomized 73 venous-ulcer patients to topical full-length thymosin beta 4 or placebo; abstract findings suggest wound-healing potential at 0.03 percent and acceptable short-term tolerability.", "what_it_does_not_show": "The abstract does not supply a decisive between-arm efficacy contrast; compression care, formulation, indication and topical route block inference to healthy-adult peptide stacks.", "confounders_present": [ "The abstract does not supply a decisive between-arm efficacy contrast; compression care, formulation, indication and topical route block inference to healthy-adult peptide stacks." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 7, "pmid": "20536458", "title": "Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts.", "citation": "Ehrlich HP, Hazard SW. Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts. Annals of the New York Academy of Sciences. 2010.", "doi": "10.1111/j.1749-6632.2010.05483.x", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20536458/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20536458/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20536458", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Local thymosin beta 4 in rat incisions improved collagen organization and wound narrowing without loss of breaking strength.", "what_it_does_not_show": "Histological organization and local rat repair do not establish injected TB-500 or combined human secretagogue recovery.", "confounders_present": [ "Histological organization and local rat repair do not establish injected TB-500 or combined human secretagogue recovery." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 8, "pmid": "19068595", "title": "[Expression of laminin 5 in rat skin wounds regulated by recombinant thymosin beta4].", "citation": "Li Y, Wang G, Yu H et al. [Expression of laminin 5 in rat skin wounds regulated by recombinant thymosin beta4]. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery. 2008.", "doi": "", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19068595/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19068595/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19068595", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Topical recombinant thymosin beta 4 in 60 rats changed laminin 5 expression and accelerated full-thickness wound closure at selected doses and times.", "what_it_does_not_show": "Wound contractions, model, route and dose-specific effects constrain translation; the marketed exact combination was absent.", "confounders_present": [ "Wound contractions, model, route and dose-specific effects constrain translation; the marketed exact combination was absent." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 9, "pmid": "19174493", "title": "Effects of an oral growth hormone secretagogue in older adults.", "citation": "White HK, Petrie CD, Landschulz W et al. Effects of an oral growth hormone secretagogue in older adults. The Journal of clinical endocrinology and metabolism. 2009.", "doi": "10.1210/jc.2008-0632", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19174493/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19174493/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19174493", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "Capromorelin in 395 older adults with mild functional limitation increased IGF-I and lean mass; pooled active groups improved tandem walk at six months and stair climb at 12 months, with glycemic and other adverse signals.", "what_it_does_not_show": "The trial stopped early under predefined effect criteria; pooled outcomes, another oral molecule, baseline limitation and longer horizon do not validate healthy-adult CJC-ipamorelin stacks.", "confounders_present": [ "The trial stopped early under predefined effect criteria; pooled outcomes, another oral molecule, baseline limitation and longer horizon do not validate healthy-adult CJC-ipamorelin stacks." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 10, "pmid": "12466367", "title": "Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men.", "citation": "Brill KT, Weltman AL, Gentili A et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. The Journal of clinical endocrinology and metabolism. 2002.", "doi": "10.1210/jc.2002-020098", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/12466367/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/12466367/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID12466367", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A randomized-order 10-man hormone crossover study found selected balance, walking and stair changes, increased fat-free mass with combined GH plus testosterone, and no strength or flexibility change.", "what_it_does_not_show": "Comparisons against baseline, short exposure, small sample and different hormone combination limit placebo-controlled stack inference; mass and muscle gene expression are not uniform functional recovery.", "confounders_present": [ "Comparisons against baseline, short exposure, small sample and different hormone combination limit placebo-controlled stack inference; mass and muscle gene expression are not uniform functional recovery." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 11, "pmid": "8156094", "title": "Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance.", "citation": "Jørgensen JO, Thuesen L, Müller J et al. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. European journal of endocrinology. 1994.", "doi": "10.1530/eje.0.1300224", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/8156094/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/8156094/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID8156094", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A three-year open continuation in 10 GH-deficient adults maintained improved muscle volume and improved exercise capacity and strength compared with the original placebo period.", "what_it_does_not_show": "Replacement of diagnosed deficiency lies outside the registered population; the uncontrolled continuation cannot establish healthy-adult stack enhancement.", "confounders_present": [ "Replacement of diagnosed deficiency lies outside the registered population; the uncontrolled continuation cannot establish healthy-adult stack enhancement." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 12, "pmid": "25358450", "title": "Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.", "citation": "González-Sales M, Barrière O, Tremblay PO et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clinical pharmacokinetics. 2015.", "doi": "10.1007/s40262-014-0202-x", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/25358450/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25358450/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25358450", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A 38-person tesamorelin analysis characterized repeated-dose pharmacokinetics in healthy subjects and HIV-infected patients.", "what_it_does_not_show": "Pharmacokinetic modeling of another GHRH analogue is not physical recovery, component synergy or clinical safety evidence for the exact stack.", "confounders_present": [ "Pharmacokinetic modeling of another GHRH analogue is not physical recovery, component synergy or clinical safety evidence for the exact stack." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 13, "pmid": "16052083", "title": "A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.", "citation": "Falutz J, Allas S, Kotler D et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS (London, England). 2005.", "doi": "10.1097/01.aids.0000180099.35146.30", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16052083/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16052083/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16052083", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A 61-person blinded TH 9507 trial in HIV-related central adiposity raised IGF-I, reduced trunk fat at the higher dose and improved selected lipid measures; visceral-fat reduction was not significant.", "what_it_does_not_show": "Indication-specific adiposity and metabolic endpoints of another molecule do not establish physical recovery or universal stack net benefit.", "confounders_present": [ "Indication-specific adiposity and metabolic endpoints of another molecule do not establish physical recovery or universal stack net benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 14, "pmid": "25038357", "title": "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.", "citation": "Stanley TL, Feldpausch MN, Oh J et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014 Jul 23-30.", "doi": "10.1001/jama.2014.8334", "pmcid": "PMC4363137", "url": "https://pubmed.ncbi.nlm.nih.gov/25038357/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25038357/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "NCT01263717", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 1:Methods:paragraph6, 2:Results:paragraph3, 2:Results:paragraph4, 2:Results:paragraph5, 2:Results:paragraph12. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Tesamorelin in 50 HIV-infected adults with abdominal fat reduced visceral and liver fat versus placebo over six months; transient fasting-glucose increase was observed at two weeks.", "what_it_does_not_show": "Different molecule and indication; adiposity endpoints and transient glycemic changes do not establish CJC-ipamorelin functional recovery or clinical net benefit.", "confounders_present": [ "Different molecule and indication; adiposity endpoints and transient glycemic changes do not establish CJC-ipamorelin functional recovery or clinical net benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 15, "pmid": "29031905", "title": "Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.", "citation": "Braun LR, Feldpausch MN, Czerwonka N et al. Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2017.", "doi": "10.1016/j.ghir.2017.10.002", "pmcid": "PMC5705434", "url": "https://pubmed.ncbi.nlm.nih.gov/29031905/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29031905/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "NCT01263717", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A secondary analysis of the 50-person tesamorelin liver-fat trial associated falling FGF 21 with liver-fat and biochemical changes; the treatment contrast for FGF 21 was only a trend.", "what_it_does_not_show": "Same-study secondary associations do not identify mediation or add an independent trial; liver-fat indication is outside healthy-adult recovery.", "confounders_present": [ "Same-study secondary associations do not identify mediation or add an independent trial; liver-fat indication is outside healthy-adult recovery." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "Secondary FGF21 analysis of NCT01263717." ] }, { "n": 16, "pmid": "24148194", "title": "Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity.", "citation": "Nellemann B, Vendelbo MH, Nielsen TS et al. Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. Acta physiologica (Oxford, England). 2014.", "doi": "10.1111/apha.12183", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24148194/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24148194/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24148194", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "Randomized GH infusion in eight healthy men promoted lipolysis and reduced clamp insulin sensitivity by approximately half, with reduced active pyruvate dehydrogenase.", "what_it_does_not_show": "Acute pharmacological GH infusion establishes a metabolic risk mechanism, not the chronic adverse-event rate of an untested secretagogue combination.", "confounders_present": [ "Acute pharmacological GH infusion establishes a metabolic risk mechanism, not the chronic adverse-event rate of an untested secretagogue combination." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 17, "pmid": "36240323", "title": "Ketone Body Infusion Abrogates Growth Hormone-Induced Lipolysis and Insulin Resistance.", "citation": "Høgild ML, Hjelholt AJ, Hansen J et al. Ketone Body Infusion Abrogates Growth Hormone-Induced Lipolysis and Insulin Resistance. The Journal of clinical endocrinology and metabolism. 2023.", "doi": "10.1210/clinem/dgac595", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/36240323/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36240323/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36240323", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "In eight healthy men receiving GH infusion, ketone infusion suppressed free fatty acids and improved glucose disposal compared with saline.", "what_it_does_not_show": "This mechanistic rescue suggests context dependence of GH-related insulin resistance; it does not establish a safe clinical peptide stack or recovery benefit.", "confounders_present": [ "This mechanistic rescue suggests context dependence of GH-related insulin resistance; it does not establish a safe clinical peptide stack or recovery benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 18, "pmid": "19549743", "title": "Growth hormone receptor antagonist treatment reduces exercise performance in young males.", "citation": "Goto K, Doessing S, Nielsen RH et al. Growth hormone receptor antagonist treatment reduces exercise performance in young males. The Journal of clinical endocrinology and metabolism. 2009.", "doi": "10.1210/jc.2009-0407", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19549743/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19549743/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19549743", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "A placebo-controlled GH-receptor antagonist trial in twenty healthy men shortened prolonged-exercise time to exhaustion without changing VO2 max.", "what_it_does_not_show": "Physiological GH contribution under receptor blockade does not prove benefit from supraphysiological stimulation or the exact peptide combination.", "confounders_present": [ "Physiological GH contribution under receptor blockade does not prove benefit from supraphysiological stimulation or the exact peptide combination." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 19, "pmid": "2003602", "title": "Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans.", "citation": "Fryburg DA, Gelfand RA, Barrett EJ. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. The American journal of physiology. 1991.", "doi": "10.1152/ajpendo.1991.260.3.E499", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/2003602/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/2003602/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID2003602", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Local GH infusion in seven healthy men increased forearm amino-acid uptake consistent with acute muscle protein synthesis.", "what_it_does_not_show": "A short regional tracer response does not demonstrate stronger muscle, healing or lasting physical recovery.", "confounders_present": [ "A short regional tracer response does not demonstrate stronger muscle, healing or lasting physical recovery." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 20, "pmid": "9005976", "title": "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.", "citation": "Vittone J, Blackman MR, Busby-Whitehead J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism: clinical and experimental. 1997.", "doi": "10.1016/s0026-0495(97)90174-8", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/9005976/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/9005976/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9005976", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Six-week nightly GHRH treatment in eleven older men increased GH and selected strength/endurance measures but not IGF-I, body composition or muscle-energy measures.", "what_it_does_not_show": "An uncontrolled before-after study of another formulation is vulnerable to practice effects and multiple outcomes; it cannot establish placebo-controlled stack benefit.", "confounders_present": [ "An uncontrolled before-after study of another formulation is vulnerable to practice effects and multiple outcomes; it cannot establish placebo-controlled stack benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 21, "pmid": "12519419", "title": "Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement.", "citation": "Weissberger AJ, Anastasiadis AD, Sturgess I et al. Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement. Clinical endocrinology. 2003.", "doi": "10.1046/j.1365-2265.2003.01700.x", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/12519419/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/12519419/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID12519419", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "Blinded GH versus placebo in thirty-three older hip-replacement patients improved postoperative four-minute walking distance and selected muscle preservation; most recipients had dose-related side effects.", "what_it_does_not_show": "Perioperative GH and underlying osteoarthritis differ from healthy-adult secretagogue stacks; selective strength findings and small sample limit generalization.", "confounders_present": [ "Perioperative GH and underlying osteoarthritis differ from healthy-adult secretagogue stacks; selective strength findings and small sample limit generalization." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 22, "pmid": "17132823", "title": "Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics.", "citation": "Krag MB, Gormsen LC, Guo Z et al. Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics. American journal of physiology. Endocrinology and metabolism. 2007.", "doi": "10.1152/ajpendo.00374.2006", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17132823/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17132823/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID17132823", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "A nine-man blinded crossover trial found GH-induced insulin resistance, including with concomitant acipimox, and increased muscle triglyceride content.", "what_it_does_not_show": "Physiological mechanism and pharmacological dose are relevant boundaries, not quantified chronic exact-stack harm.", "confounders_present": [ "Physiological mechanism and pharmacological dose are relevant boundaries, not quantified chronic exact-stack harm." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 23, "pmid": "15472216", "title": "Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial.", "citation": "Esposito JG, Thomas SG, Kingdon L et al. Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. The Journal of clinical endocrinology and metabolism. 2004.", "doi": "10.1210/jc.2004-0451", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/15472216/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/15472216/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID15472216", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A twelve-person blinded crossover GH trial in HIV-associated wasting improved peripheral oxygen extraction during exercise.", "what_it_does_not_show": "Disease wasting, recombinant GH and oxygen-extraction physiology cannot validate recovery enhancement in nondeficient healthy adults.", "confounders_present": [ "Disease wasting, recombinant GH and oxygen-extraction physiology cannot validate recovery enhancement in nondeficient healthy adults." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 24, "pmid": "18000087", "title": "Enhancement of muscle mitochondrial function by growth hormone.", "citation": "Short KR, Moller N, Bigelow ML et al. Enhancement of muscle mitochondrial function by growth hormone. The Journal of clinical endocrinology and metabolism. 2008.", "doi": "10.1210/jc.2007-1814", "pmcid": "PMC2243230", "url": "https://pubmed.ncbi.nlm.nih.gov/18000087/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18000087/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18000087", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A nine-person randomized GH-infusion crossover increased mitochondrial oxidative capacity and whole-body protein synthesis, with glucose, insulin and fatty-acid changes.", "what_it_does_not_show": "Mitochondrial and tracer endpoints are biomarkers; there was no functional recovery measurement or exact combination.", "confounders_present": [ "Mitochondrial and tracer endpoints are biomarkers; there was no functional recovery measurement or exact combination." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 25, "pmid": "9467534", "title": "MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.", "citation": "Murphy MG, Plunkett LM, Gertz BJ et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism. 1998.", "doi": "10.1210/jcem.83.2.4551", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/9467534/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/9467534/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9467534", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "MK-677 in eight calorically restricted healthy adults improved nitrogen balance and GH/IGF-I over seven treatment days versus placebo.", "what_it_does_not_show": "Diet-induced nitrogen wasting is a short metabolic endpoint, not strength or return to activity; another oral molecule cannot establish stack efficacy.", "confounders_present": [ "Diet-induced nitrogen wasting is a short metabolic endpoint, not strength or return to activity; another oral molecule cannot establish stack efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 26, "pmid": "26906526", "title": "Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.", "citation": "Temel JS, Abernethy AP, Currow DC et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. The Lancet. Oncology. 2016.", "doi": "10.1016/S1470-2045(15)00558-6", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/26906526/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26906526/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "ROMANA1-and-ROMANA2", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "The two ROMANA trials randomized 979 lung-cancer cachexia patients; anamorelin increased lean mass but did not improve co-primary handgrip strength, with some severe hyperglycemia.", "what_it_does_not_show": "Cancer cachexia and a different oral ghrelin agonist are outside the nominal population; null handgrip is a mass-versus-function boundary rather than proof all axis stimulation fails.", "confounders_present": [ "Cancer cachexia and a different oral ghrelin agonist are outside the nominal population; null handgrip is a mass-versus-function boundary rather than proof all axis stimulation fails." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [ "One report contains two trials; counts are reports and study units separately." ] }, { "n": 27, "pmid": "41181834", "title": "Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.", "citation": "Yamamoto K, Kurokawa Y, Miyazaki Y et al. Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial. EClinicalMedicine. 2025.", "doi": "10.1016/j.eclinm.2025.103500", "pmcid": "PMC12572812", "url": "https://pubmed.ncbi.nlm.nih.gov/41181834/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41181834/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41181834", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "A 203-person open randomized gastric-cancer cachexia trial did not meet its primary between-arm lean-mass endpoint at eight weeks; hyperglycemia occurred in the active arm.", "what_it_does_not_show": "Modified per-protocol analysis, no placebo blinding and another disease-specific drug constrain inference; a nonsignificant trend is not established benefit.", "confounders_present": [ "Modified per-protocol analysis, no placebo blinding and another disease-specific drug constrain inference; a nonsignificant trend is not established benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 28, "pmid": "29864719", "title": "Analysis of new growth promoting black market products.", "citation": "Krug O, Thomas A, Malerød-Fjeld H et al. Analysis of new growth promoting black market products. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2018.", "doi": "10.1016/j.ghir.2018.05.001", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29864719/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29864719/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29864719", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Mass-spectrometric testing identified altered GH and glycine-extended GHRP-2, GHRP-6 and ipamorelin in black-market growth products, with synthetic confirmation of selected identities.", "what_it_does_not_show": "Analytical identity evidence from sampled products cannot estimate market-wide adulteration prevalence or clinical efficacy and harms.", "confounders_present": [ "Analytical identity evidence from sampled products cannot estimate market-wide adulteration prevalence or clinical efficacy and harms." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 29, "pmid": "39992021", "title": "Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.", "citation": "Laird BJA, Skipworth R, Bonomi PD et al. Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2. Journal of cachexia, sarcopenia and muscle. 2025.", "doi": "10.1002/jcsm.13732", "pmcid": "PMC11848863", "url": "https://pubmed.ncbi.nlm.nih.gov/39992021/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39992021/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "ROMANA1-and-ROMANA2", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A post hoc ROMANA analysis of 795 patients associated greater clinical improvements with selected baseline inflammation and wasting groups, including subgroup handgrip findings.", "what_it_does_not_show": "This is the same parent trials and post hoc subgroup analysis; it does not erase the null co-primary handgrip results or create a new independent functional trial.", "confounders_present": [ "This is the same parent trials and post hoc subgroup analysis; it does not erase the null co-primary handgrip results or create a new independent functional trial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "Post hoc pooled subgroup analysis of ROMANA1/2." ] }, { "n": 30, "pmid": "31074178", "title": "Appetite and food intake results from phase I studies of anamorelin.", "citation": "Blum RA, Mair S, Duus EM. Appetite and food intake results from phase I studies of anamorelin. Journal of cachexia, sarcopenia and muscle. 2019.", "doi": "10.1002/jcsm.12439", "pmcid": "PMC6818453", "url": "https://pubmed.ncbi.nlm.nih.gov/31074178/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31074178/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID31074178", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Two small blinded healthy-adult phase 1 anamorelin studies increased hunger and, at selected doses, caloric intake.", "what_it_does_not_show": "Appetite effects show a possible non-GH route to weight gain; they are not recovery, stack synergy or proof that increased mass means improved function.", "confounders_present": [ "Appetite effects show a possible non-GH route to weight gain; they are not recovery, stack synergy or proof that increased mass means improved function." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 31, "pmid": "28830317", "title": "Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.", "citation": "Sigalos JT, Pastuszak AW, Allison A et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. American journal of men's health. 2017.", "doi": "10.1177/1557988317718662", "pmcid": "PMC5675260", "url": "https://pubmed.ncbi.nlm.nih.gov/28830317/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28830317/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28830317", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A retrospectively selected fourteen-man testosterone-treated cohort receiving GHRP-2/GHRP-6/sermorelin showed increased IGF-I.", "what_it_does_not_show": "Only fourteen of 105 met compliance criteria, co-treatments varied, and no credible control or physical outcome was measured; another triple combination does not validate CJC-ipamorelin.", "confounders_present": [ "Only fourteen of 105 met compliance criteria, co-treatments varied, and no credible control or physical outcome was measured; another triple combination does not validate CJC-ipamorelin." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 32, "pmid": "9849822", "title": "Ipamorelin, the first selective growth hormone secretagogue.", "citation": "Raun K, Hansen BS, Johansen NL et al. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. 1998.", "doi": "10.1530/eje.0.1390552", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/9849822/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/9849822/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9849822", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Ipamorelin stimulated GH in rat pituitary cells, rats and swine; antagonist profiling supported a GHRP-like receptor and comparatively selective hormonal effects in swine.", "what_it_does_not_show": "Preclinical selectivity and acute GH release do not establish healthy-adult recovery or long-term combination safety.", "confounders_present": [ "Preclinical selectivity and acute GH release do not establish healthy-adult recovery or long-term combination safety." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 33, "pmid": "10373343", "title": "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.", "citation": "Johansen PB, Nowak J, Skjaerbaek C et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1999.", "doi": "10.1054/ghir.1999.9998", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10373343/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10373343/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10373343", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Ipamorelin increased longitudinal bone growth and body-weight gain over fifteen days in adult female rats, without measured total IGF-I change.", "what_it_does_not_show": "Rat longitudinal growth is not adult human injury recovery; species, growth physiology and formulation boundaries remain.", "confounders_present": [ "Rat longitudinal growth is not adult human injury recovery; species, growth physiology and formulation boundaries remain." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 34, "pmid": "19386527", "title": "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.", "citation": "Sackmann-Sala L, Ding J, Frohman LA et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2009.", "doi": "10.1016/j.ghir.2009.03.001", "pmcid": "PMC2787983", "url": "https://pubmed.ncbi.nlm.nih.gov/19386527/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19386527/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "CJC-pulsatility-cohort", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:2. Materials and Methods:paragraph0, 1:2. Materials and Methods:paragraph1, 1:2. Materials and Methods:paragraph13, 2:3. Results:paragraph2, 2:3. Results:paragraph3, 2:3. Results:paragraph4. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "CJC-1295-associated serum proteomic changes in eleven healthy men supplied candidate markers of GH/IGF-I activity.", "what_it_does_not_show": "Before-after protein spots and correlations do not measure recovery or isolate mediation; participant overlap with the parent CJC pulsatility work must be grouped.", "confounders_present": [ "Before-after protein spots and correlations do not measure recovery or isolate mediation; participant overlap with the parent CJC pulsatility work must be grouped." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "Subset of prior CJC pulsatility cohort; no new independent participants." ] }, { "n": 35, "pmid": "11162489", "title": "Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.", "citation": "Lall S, Tung LY, Ohlsson C et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications. 2001.", "doi": "10.1006/bbrc.2000.4065", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/11162489/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/11162489/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID11162489", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Ipamorelin increased adiposity and food intake in GH-intact and GH-deficient mice, indicating GH-independent actions differing from GH itself.", "what_it_does_not_show": "Mouse adiposity does not establish a human harm rate; it challenges assuming every secretagogue effect is explained by the GH axis.", "confounders_present": [ "Mouse adiposity does not establish a human harm rate; it challenges assuming every secretagogue effect is explained by the GH axis." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 36, "pmid": "19289567", "title": "Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.", "citation": "Venkova K, Mann W, Nelson R et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics. 2009.", "doi": "10.1124/jpet.108.149211", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19289567/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19289567/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19289567", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Intravenous ipamorelin improved selected bowel-transit and, with repeated dosing, output and intake measures in a rat postoperative-ileus model.", "what_it_does_not_show": "Rodent gastrointestinal recovery did not translate to the primary human ipamorelin meal-tolerance result; healthy-adult muscular recovery was not tested.", "confounders_present": [ "Rodent gastrointestinal recovery did not translate to the primary human ipamorelin meal-tolerance result; healthy-adult muscular recovery was not tested." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 37, "pmid": "21204297", "title": "Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.", "citation": "Henninge J, Pepaj M, Hullstein I et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis. 2010.", "doi": "10.1002/dta.233", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/21204297/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21204297/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID21204297", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Mass spectrometry identified a twenty-nine-amino-acid peptide marketed as CJC-1295 in an unknown pharmaceutical preparation.", "what_it_does_not_show": "A market label and a sequence are insufficient evidence of equivalence to the long-acting albumin-binding clinical formulation or of efficacy, purity and safety across products.", "confounders_present": [ "A market label and a sequence are insufficient evidence of equivalence to the long-acting albumin-binding clinical formulation or of efficacy, purity and safety across products." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 38, "pmid": "27186127", "title": "Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.", "citation": "Greenwood-Van Meerveld B, Tyler K, Mohammadi E et al. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology. 2012.", "doi": "10.2147/JEP.S35396", "pmcid": "PMC4863553", "url": "https://pubmed.ncbi.nlm.nih.gov/27186127/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27186127/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID27186127", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Ipamorelin improved postoperative gastric emptying in rats and rescued contractile responses in isolated gastric tissue.", "what_it_does_not_show": "Single-agent animal motility does not establish a healthy-adult stack or overcome the human ileus trial's null efficacy result.", "confounders_present": [ "Single-agent animal motility does not establish a healthy-adult stack or overcome the human ileus trial's null efficacy result." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 39, "pmid": "23417424", "title": "Hepatic growth hormone resistance after acute injury.", "citation": "Corrick RM, Li L, Frank SJ et al. Hepatic growth hormone resistance after acute injury. Endocrinology. 2013.", "doi": "10.1210/en.2012-2134", "pmcid": "PMC3602625", "url": "https://pubmed.ncbi.nlm.nih.gov/23417424/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23417424/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23417424", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Mouse acute-injury and hemorrhage models showed rapidly impaired hepatic GH signaling and altered receptor features despite GH challenge.", "what_it_does_not_show": "A signaling-resistance model does not establish clinical recovery benefit or justify increasing doses; injured physiology differs from healthy adults.", "confounders_present": [ "A signaling-resistance model does not establish clinical recovery benefit or justify increasing doses; injured physiology differs from healthy adults." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 40, "pmid": "29464859", "title": "Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study.", "citation": "Fernández-Mayola M, Betancourt L, Molina-Kautzman A et al. Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study. International wound journal. 2018.", "doi": "10.1111/iwj.12895", "pmcid": "PMC7949743", "url": "https://pubmed.ncbi.nlm.nih.gov/29464859/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29464859/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29464859", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "GHRP-6 prevented hypertrophic scarring in a rabbit model but did not significantly reverse established scars.", "what_it_does_not_show": "Another peptide, local route and stage-specific injury model are not direct CJC-ipamorelin clinical evidence; early proteomics do not prove the causal mediator.", "confounders_present": [ "Another peptide, local route and stage-specific injury model are not direct CJC-ipamorelin clinical evidence; early proteomics do not prove the causal mediator." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 41, "pmid": "9790334", "title": "Growth hormone treatment in pediatric burns: a safe therapeutic approach.", "citation": "Ramirez RJ, Wolf SE, Barrow RE et al. Growth hormone treatment in pediatric burns: a safe therapeutic approach. Annals of surgery. 1998.", "doi": "10.1097/00000658-199810000-00001", "pmcid": "PMC1191513", "url": "https://pubmed.ncbi.nlm.nih.gov/9790334/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/9790334/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9790334", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A pediatric severe-burn report combining randomized and matched comparisons found similar mortality but greater hyperglycemia and insulin requirements with GH.", "what_it_does_not_show": "Retrospective aggregation, mixed controls and pediatric burn indication prevent extrapolating reported safety to critically ill adults or healthy-adult peptide stacks.", "confounders_present": [ "Retrospective aggregation, mixed controls and pediatric burn indication prevent extrapolating reported safety to critically ill adults or healthy-adult peptide stacks." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 42, "pmid": "28976342", "title": "Topical Growth Hormone Accelerates Wound Healing in Mice.", "citation": "Messias de Lima CF, de Araújo Vieira LF, de Carvalho Wanderley LA et al. Topical Growth Hormone Accelerates Wound Healing in Mice. Wounds : a compendium of clinical research and practice. 2017.", "doi": "", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/28976342/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28976342/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28976342", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Topical GH accelerated wound closure and selected repair histology in mice compared with vehicle.", "what_it_does_not_show": "Local GH in one skin-wound species does not demonstrate injected secretagogue stack benefit or endogenous necessity.", "confounders_present": [ "Local GH in one skin-wound species does not demonstrate injected secretagogue stack benefit or endogenous necessity." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 43, "pmid": "9915674", "title": "Effect of growth hormone therapy in burn patients on conservative treatment.", "citation": "Singh KP, Prasad R, Chari PS et al. Effect of growth hormone therapy in burn patients on conservative treatment. Burns : journal of the International Society for Burn Injuries. 1998.", "doi": "10.1016/s0305-4179(98)00113-2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/9915674/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/9915674/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9915674", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A small comparative burn series reported better wound healing and other clinical measures with GH plus conservative care, alongside metabolic adverse changes.", "what_it_does_not_show": "Thirteen treated and nine control patients with nonrandomized allocation cannot establish a reliable mortality benefit or general healthy-adult recovery effect.", "confounders_present": [ "Thirteen treated and nine control patients with nonrandomized allocation cannot establish a reliable mortality benefit or general healthy-adult recovery effect." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 44, "pmid": "23636184", "title": "Human growth hormone may be detrimental when used to accelerate recovery from acute tendon-bone interface injuries.", "citation": "Baumgarten KM, Oliver HA, Foley J et al. Human growth hormone may be detrimental when used to accelerate recovery from acute tendon-bone interface injuries. The Journal of bone and joint surgery. American volume. 2013.", "doi": "10.2106/JBJS.L.00222", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/23636184/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23636184/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23636184", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Randomized rat rotator-cuff repair experiments found no benefit of postoperative GH and worse ultimate failure load with prolonged high-dose perioperative GH.", "what_it_does_not_show": "The harm is specific to an animal tendon-bone injury and high dosing; it does not prove every human peptide formulation harms tendons.", "confounders_present": [ "The harm is specific to an animal tendon-bone injury and high dosing; it does not prove every human peptide formulation harms tendons." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 45, "pmid": "20880960", "title": "Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts.", "citation": "Tokura Y, Nakayama Y, Fukada S et al. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. Journal of biochemistry. 2011.", "doi": "10.1093/jb/mvq115", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20880960/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20880960/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20880960", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Injured mouse muscle increased thymosin beta 4 expression, and peptide forms increased myoblast chemotaxis and cell-culture wound closure.", "what_it_does_not_show": "Expression and cellular migration do not establish endogenous necessity, full in-vivo muscle recovery or human injected peptide efficacy.", "confounders_present": [ "Expression and cellular migration do not establish endogenous necessity, full in-vivo muscle recovery or human injected peptide efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 46, "pmid": "42542926", "title": "Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.", "citation": "Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery. 2026.", "doi": "10.52312/jdrs.2026.2951", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42542926/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42542926/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42542926", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "A thirty-two-rat Achilles repair study found a significant mechanical advantage for TB-500 alone; combined BPC-157/TB-500 did not confer additional benefit over individual treatment.", "what_it_does_not_show": "This recent four-arm animal experiment tests another exact stack, not CJC-ipamorelin; small groups and four-week surgical model do not establish human efficacy, safety or dose equivalence.", "confounders_present": [ "This recent four-arm animal experiment tests another exact stack, not CJC-ipamorelin; small groups and four-week surgical model do not establish human efficacy, safety or dose equivalence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 47, "pmid": "10469335", "title": "Thymosin beta4 accelerates wound healing.", "citation": "Malinda KM, Sidhu GS, Mani H et al. Thymosin beta4 accelerates wound healing. The Journal of investigative dermatology. 1999.", "doi": "10.1046/j.1523-1747.1999.00708.x", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10469335/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10469335/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10469335", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Topical or intraperitoneal full-length thymosin beta 4 improved rat skin reepithelialization and contraction, with increased collagen and angiogenesis.", "what_it_does_not_show": "Rat skin closure and cultured keratinocyte migration do not establish marketed TB-500 identity or healthy-adult CJC-ipamorelin recovery.", "confounders_present": [ "Rat skin closure and cultured keratinocyte migration do not establish marketed TB-500 identity or healthy-adult CJC-ipamorelin recovery." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 48, "pmid": "23523891", "title": "Thymosin β4 enhances the healing of medial collateral ligament injury in rat.", "citation": "Xu B, Yang M, Li Z et al. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regulatory peptides. 2013.", "doi": "10.1016/j.regpep.2013.03.026", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/23523891/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23523891/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23523891", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Local thymosin beta 4 in fibrin sealant improved four-week rat medial-collateral-ligament histology and biomechanical properties.", "what_it_does_not_show": "Local delivery, animal injury and another molecule limit translation; it is not a controlled human stack or proof of systemic safety.", "confounders_present": [ "Local delivery, animal injury and another molecule limit translation; it is not a controlled human stack or proof of systemic safety." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 49, "pmid": "24993983", "title": "Effects of thymosin β4 on wound healing of rat palatal mucosa.", "citation": "Zhu T, Park HC, Son KM et al. Effects of thymosin β4 on wound healing of rat palatal mucosa. International journal of molecular medicine. 2014.", "doi": "10.3892/ijmm.2014.1832", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24993983/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24993983/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24993983", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Thymosinbeta 4 enhanced rat palatal-wound closure and primary-cell migration, with MMP 2 and VEGF changes.", "what_it_does_not_show": "Small animal and cell assays show partial repair support, not a human functional recovery or exact-stack clinical outcome.", "confounders_present": [ "Small animal and cell assays show partial repair support, not a human functional recovery or exact-stack clinical outcome." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 50, "pmid": "17923415", "title": "Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing.", "citation": "Li X, Zheng L, Peng F et al. Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing. Protein expression and purification. 2007.", "doi": "10.1016/j.pep.2007.08.011", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17923415/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17923415/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID17923415", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "An originally produced recombinant human thymosin beta 4 preparation promoted full-thickness wound healing in mice.", "what_it_does_not_show": "Recombinant expression was a production method, not endogenous necessity; product, route and animal scope prevent clinical stack inference.", "confounders_present": [ "Recombinant expression was a production method, not endogenous necessity; product, route and animal scope prevent clinical stack inference." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 51, "pmid": "18981485", "title": "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.", "citation": "Nass R, Pezzoli SS, Oliveri MC et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of internal medicine. 2008.", "doi": "10.7326/0003-4819-149-9-200811040-00003", "pmcid": "PMC2757071", "url": "https://pubmed.ncbi.nlm.nih.gov/18981485/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18981485/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18981485", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph1, 1:METHODS:paragraph10, 1:METHODS:paragraph11, 1:METHODS:paragraph18, 1:METHODS:paragraph19, 2:RESULTS:paragraph4, 2:RESULTS:paragraph5, 2:RESULTS:paragraph15, 2:RESULTS:paragraph16, 2:RESULTS:paragraph20, 2:RESULTS:paragraph21. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "A blinded 65-person MK-677 trial increased GH, IGF-I and fat-free mass over twelve months but showed no significant strength or function improvement; glucose rose and insulin sensitivity fell.", "what_it_does_not_show": "Primary power focused on fat-free mass and visceral fat; secondary functional nulls do not establish equivalence, and another oral agent and older population do not test the exact stack.", "confounders_present": [ "Primary power focused on fat-free mass and visceral fat; secondary functional nulls do not establish equivalence, and another oral agent and older population do not test the exact stack." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 52, "pmid": "20439575", "title": "The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial.", "citation": "Meinhardt U, Nelson AE, Hansen JL et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Annals of internal medicine. 2010.", "doi": "10.7326/0003-4819-152-9-201005040-00007", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20439575/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20439575/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20439575", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "A blinded ninety-six-athlete trial found an approximately 3.9 percent GH-associated sprint-capacity increase over eight weeks, with no significant strength, aerobic endurance or jump-power change; lean-mass gain largely reflected extracellular water.", "what_it_does_not_show": "Different hormones and a performance endpoint do not test exact peptide recovery; sprint gain was not maintained after six-week washout, and athletic importance and safety were uncertain.", "confounders_present": [ "Different hormones and a performance endpoint do not test exact peptide recovery; sprint gain was not maintained after six-week washout, and athletic importance and safety were uncertain." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 53, "pmid": "1550219", "title": "Effect of growth hormone and resistance exercise on muscle growth in young men.", "citation": "Yarasheski KE, Campbell JA, Smith K et al. Effect of growth hormone and resistance exercise on muscle growth in young men. The American journal of physiology. 1992.", "doi": "10.1152/ajpendo.1992.262.3.E261", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/1550219/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/1550219/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID1550219", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "In sixteen young men randomized to identical resistance training with GH or placebo, GH increased fat-free mass and whole-body synthesis but did not add muscle-strength or quadriceps-synthesis gain over twelve weeks.", "what_it_does_not_show": "Small trial and recombinant GH differ from the exact stack; similar training gains do not prove all GH-axis exposures ineffective or establish equivalence.", "confounders_present": [ "Small trial and recombinant GH differ from the exact stack; similar training gains do not prove all GH-axis exposures ineffective or establish equivalence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 54, "pmid": "7864103", "title": "Effect of growth hormone and resistance exercise on muscle growth and strength in older men.", "citation": "Yarasheski KE, Zachwieja JJ, Campbell JA et al. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. The American journal of physiology. 1995.", "doi": "10.1152/ajpendo.1995.268.2.E268", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/7864103/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/7864103/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID7864103", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "In twenty-three older men assigned to the same resistance training with GH or placebo, fat-free mass and water rose more with GH but muscle protein synthesis and strength increments were similar.", "what_it_does_not_show": "The trial supplies a proxy-versus-function and concurrent-training boundary; another molecule and small unequal groups do not test exact-combination recovery.", "confounders_present": [ "The trial supplies a proxy-versus-function and concurrent-training boundary; another molecule and small unequal groups do not test exact-combination recovery." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 55, "pmid": "10477776", "title": "Increased mortality associated with growth hormone treatment in critically ill adults.", "citation": "Takala J, Ruokonen E, Webster NR et al. Increased mortality associated with growth hormone treatment in critically ill adults. The New England journal of medicine. 1999.", "doi": "10.1056/NEJM199909093411102", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10477776/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10477776/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10477776", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "Two blinded trials in 532 critically ill adults found higher mortality with high-dose GH: 39 versus 20 percent and 44 versus 18 percent; survivors also had longer ventilation and stays.", "what_it_does_not_show": "This is a serious randomized safety boundary for high-dose GH in prolonged critical illness, not a measured mortality rate for healthy-adult CJC-ipamorelin stacks.", "confounders_present": [ "This is a serious randomized safety boundary for high-dose GH in prolonged critical illness, not a measured mortality rate for healthy-adult CJC-ipamorelin stacks." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [ "One report includes Finnish and multinational randomized trials; retain both experiments but one report count." ] }, { "n": 56, "pmid": "12425705", "title": "Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial.", "citation": "Blackman MR, Sorkin JD, Münzer T et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002.", "doi": "10.1001/jama.288.18.2282", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/12425705/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/12425705/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID12425705", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "A blinded 131-person older-adult factorial GH/sex-steroid trial increased lean mass; combined GH-testosterone improved men's VO2 max, while women's strength/endurance were not significantly improved and metabolic or edema-related adverse events were frequent.", "what_it_does_not_show": "Different hormone combination, sex-specific responses and 26-week exposure do not establish exact-stack recovery; lean mass alone and correlational changes do not identify mediation.", "confounders_present": [ "Different hormone combination, sex-specific responses and 26-week exposure do not establish exact-stack recovery; lean mass alone and correlational changes do not identify mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 61, "verified": 61, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.", "specific_trigger": "Controlled human CJC-1295 and ipamorelin reports establish single-agent GH-axis activity. For the recovery mechanism, these are endocrine biomarkers; the exact combination has no verified human functional result in this search. The biomarker cap is applied to inference from target engagement to recovery, not a denial that pharmacodynamic stimulation occurred.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.", "specific_trigger": "Partial biological support comes from single-agent human pharmacodynamics and related repair experiments. No examined report directly demonstrates a positive functional recovery effect of the exact CJC-1295 plus ipamorelin combination in the registered population. Different hormones, molecules, disease indications and animal injuries do not cross its clinical Δ threshold.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC3", "cap": "Α", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Use when the hypothesis is mostly a grand narrative with weak intervention support.", "specific_trigger": "The claim that component evidence establishes all marketed stack benefits remains an unsupported generalization. The new BPC-157/TB-500 four-arm rat study supplies a useful counterexample to automatic additivity, while its own positive single-agent mechanical result retains its rat scope. Approved or studied single-agent indications remain distinct.", "resulting_ceiling": "Α" }, { "subclaim_id": "SC4", "cap": "Α", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Use when the hypothesis is mostly a grand narrative with weak intervention support.", "specific_trigger": "A broad net-benefit claim across promoted healthy-adult uses has no verified exact-stack controlled benefit-harm comparison. Short CJC tolerability, ipamorelin ileus monitoring, GH-axis metabolic risks and sampled product-identity problems cannot be combined into a measured exact-stack net benefit or universal toxicity conclusion.", "resulting_ceiling": "Α" } ], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Injectable CJC-1295 combined with ipamorelin improves physical recovery in adults without diagnosed growth-hormone deficiency.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "A related animal experiment can demonstrate repair in its own model, and a different human GH-axis agent can show an indication-specific clinical effect. Neither satisfies the exact combination/population clinical threshold. Universal cap 4 governs the inference from endocrine-only support to recovery, while system and intervention identity govern translation. No cap is re-applied to erase a true same-scope complementary causal set; none was verified for the nominal claim.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "Biomarker-only endocrine engagement supports target activity but not functional recovery." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Controlled human CJC-1295 and ipamorelin reports establish single-agent GH-axis activity. For the recovery mechanism, these are endocrine biomarkers; the exact combination has no verified human functional result in this search. The biomarker cap is applied to inference from target engagement to recovery, not a denial that pharmacodynamic stimulation occurred.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "No verified exact-combination clinical perturbation with a positive functional result." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Partial biological support comes from single-agent human pharmacodynamics and related repair experiments. No examined report directly demonstrates a positive functional recovery effect of the exact CJC-1295 plus ipamorelin combination in the registered population. Different hormones, molecules, disease indications and animal injuries do not cross its clinical Δ threshold.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "Component, species, route and disease substitutions do not establish the marketed combination." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "The claim that component evidence establishes all marketed stack benefits remains an unsupported generalization. The new BPC-157/TB-500 four-arm rat study supplies a useful counterexample to automatic additivity, while its own positive single-agent mechanical result retains its rat scope. Approved or studied single-agent indications remain distinct.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "No exact-stack controlled net-benefit comparison." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "A broad net-benefit claim across promoted healthy-adult uses has no verified exact-stack controlled benefit-harm comparison. Short CJC tolerability, ipamorelin ileus monitoring, GH-axis metabolic risks and sampled product-identity problems cannot be combined into a measured exact-stack net benefit or universal toxicity conclusion.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "A preregistered exact-formulation placebo-controlled combination/component-dismantling clinical test with positive patient-relevant function or healing, adequate power and concurrent adverse-event assessment in the defined population." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "A preregistered exact-formulation placebo-controlled combination/component-dismantling clinical test with positive patient-relevant function or healing, adequate power and concurrent adverse-event assessment in the defined population." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "A preregistered exact-formulation placebo-controlled combination/component-dismantling clinical test with positive patient-relevant function or healing, adequate power and concurrent adverse-event assessment in the defined population." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "A preregistered exact-formulation placebo-controlled combination/component-dismantling clinical test with positive patient-relevant function or healing, adequate power and concurrent adverse-event assessment in the defined population." } ], "generalization_check": { "generalization_tested": "no", "context_boundary_mapped": "no", "internal_negative_controls": "No direct exact-stack internal negative control was found. Comparator boundaries include MK-677 hormone/mass increases without functional gains, ipamorelin rat ileus benefit versus human primary-null efficacy, GH hip-replacement positives versus other indications, GH tendon-bone null/harm, and no added benefit of BPC-157/TB-500 over components in one rat model.", "note": "Direct clinical generalization of the exact combination has not been tested in the examined corpus. These neighboring boundaries constrain analogy; they do not constitute a mapped efficacy boundary for a successful exact-stack trial." }, "falsification_patterns_met": [], "pitfalls_flagged": [ { "pitfall": "Confirmation by biomarker", "where": "GH/IGF-I, tracer synthesis and DXA lean mass are substituted for physical recovery." }, { "pitfall": "Selective generalization", "where": "Deficiency replacement, postoperative care and animal injuries are extrapolated to nondeficient adult stacks." }, { "pitfall": "Mechanism conflation", "where": "Full-length thymosin beta4, TB-500 products, CJC-1295 formulations and ghrelin agonists are treated as interchangeable." }, { "pitfall": "Negative field-valid perturbation read as a crossed threshold", "where": "The human ipamorelin ileus null and GH tendon-bone negatives remain contrasts, not positive Δ crossings." }, { "pitfall": "Replication confused with reproduction", "where": "CJC proteomics and ROMANA post hoc analyses are grouped with parent cohorts." }, { "pitfall": "Scope fitted to the result", "where": "Post hoc ROMANA subgroup positives cannot replace the original whole-trial primary result." } ], "causal_tally_audit": { "tally_claimed_by_document": 0, "tally_after_audit": 0, "tally_unit": "Positive qualifying study units across scoped subclaims, not independent causal lines or full-claim necessity/sufficiency.", "screened_discriminating_contrasts": 20, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "Zero positive study units qualify the exact healthy-adult CJC-1295 plus ipamorelin recovery claim. Positive functional comparators are intentionally retained without being counted as nominal crossings.", "Protein spots and endocrine pharmacodynamics are not independent recovery causal lines.", "A product-identification experiment informs formulation equivalence, not patient outcome prevalence." ] }, "steelman": { "case_one_rung_higher": "One rung above (Δ): single-agent GH-axis activation is direct, a receptor-blockade experiment implicates physiological GH in exercise capacity, and selected controlled GH or capromorelin trials improve function. That makes a combination recovery effect scientifically possible and supplies a strong rationale for a direct trial. The blinded recreational-athlete GH trial PMID20439575 also shows a genuine short-lived sprint-capacity benefit, making a blanket denial of performance effects untenable.", "case_one_rung_lower": "One rung below (Β): direct exact-combination human recovery is absent, and marketing may only associate exposure with subjective improvement or concurrent rehabilitation. If mechanistic evidence were merely co-occurrence, Β would follow.", "which_rejected": "Δ is rejected because no positive controlled exact-combination recovery endpoint in the registered population was verified; hormone stimulation cannot cross the phenotype threshold. Β is rejected because human component pharmacodynamics and preclinical receptor/repair interventions supply more than co-occurrence, although they leave the human combination dependency unshown. Thus Γ remains the primary-subclaim level.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: A preregistered blinded factorial comparison of formulation-verified CJC-1295, ipamorelin, their exact combination and placebo in a predefined adult recovery setting without diagnosed GH deficiency, with matched rehabilitation and an independently assessed functional recovery endpoint over 4–24 weeks." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "Multiple independent human studies support the level's components (two blinded CJC-1295 ascending-dose and pulsatility reports, human ipamorelin pharmacodynamics, and several controlled GH or secretagogue functional trials), but methodological heterogeneity persists across molecules, routes, exposures and endpoints, and the exact combination is untested. Evidence density and reproducibility set the Moderate band, not the reviewer's access depth and not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "The preregistered primary-subclaim rule returns SC2 Γ: mechanistic plausibility and partial system support are present, but an exact-combination positive clinical recovery experiment is missing. This is an unproven benefit claim, not a claim that every peptide is ineffective or that future recovery benefit is impossible. Fifty-plus examined originals are mostly component, mechanism, comparator and indication-boundary reports, not fifty trials of the marketed combination." }, "role_of_mechanism": { "classification": "epiphenomenon", "derivation_step_matched": 2, "derivation": "For the registered combination and physical recovery, no causal dependency has been demonstrated in either direction. The required framework role is therefore epiphenomenon as an evidence-state classification, not proof that physiological GH or either component is biologically inactive. Endocrine perturbation is established separately.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "CJC-1295 human endocrine/proteomic experiments, ipamorelin preclinical-to-ileus work, and the 2026 BPC-157/TB-500 rat Achilles experiment are verified adjacent mechanistic or scoped work. No verified active exact-combination clinical recovery programme was identified in this bounded search.", "justification": "CJC-1295 human endocrine/proteomic experiments, ipamorelin preclinical-to-ileus work, and the 2026 BPC-157/TB-500 rat Achilles experiment are verified adjacent mechanistic or scoped work. No verified active exact-combination clinical recovery programme was identified in this bounded search." }, "stability": { "value": "Stable", "trigger": "A registered, formulation-verified, blinded exact-combination recovery trial could raise the score; none was verified as underway. No named pending result currently supplies a directional trigger.", "justification": "A registered, formulation-verified, blinded exact-combination recovery trial could raise the score; none was verified as underway. No named pending result currently supplies a directional trigger." }, "divergence": { "implied_level": null, "implied_level_basis": "No single field-implied level is defensible from conflicting framings.", "assessed_level": "Γ", "gap_in_rungs": null, "value": "Contested", "justification": "No manufactured field consensus or arithmetic gap. Artifact for the split: clinic and vendor framing of the exact stack as an established recovery aid implies a high rung, while the examined trial literature contains no exact-combination functional test and several same-axis functional nulls, implying the bottom of the ladder for that claim (PMID18981485,25331030,1550219,7864103)." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "none assigned", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": true, "new_level": "Γ", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "A preregistered blinded factorial comparison of formulation-verified CJC-1295, ipamorelin, their exact combination and placebo in a predefined adult recovery setting without diagnosed GH deficiency, with matched rehabilitation and an independently assessed functional recovery endpoint over 4–24 weeks.", "readout": "A prespecified clinically meaningful return-to-activity or validated physical-function endpoint; hormone, body-water and mass outcomes secondary; adverse events and glycemic change analyzed alongside benefit", "critical_control": "Exact molecular identity and batch verification, matched placebo and rehabilitation, component arms, blinded assessors, baseline injury/health eligibility, intention-to-treat analysis and prespecified clinically important effect", "supporting_result": "The combination improves the prespecified functional endpoint beyond placebo with a credible benefit-harm balance; component arms identify whether additivity or a single component explains the result", "falsifying_result": "Confirmed target engagement with no clinically meaningful function or healing advantage at adequate precision, or harms that outweigh the measured benefit; avoid interpreting underpowered nonsignificance as equivalence" } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Direct human functional outcomes for the exact combination.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Formulation equivalence between long-acting albumin-binding CJC-1295 and products sold under similar names.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "Component-dismantling evidence and patient-relevant synergy rather than hormone synergy.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "Adequately powered functional endpoints and distinction between contractile tissue, fluid, appetite and measured recovery.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 5", "statement": "Longer-term controlled safety and net benefit under verified product exposure.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 6", "statement": "Translation of full-length thymosin beta4 and newer TB-500 animal mechanical results to defined human indications without treating different peptides as one class.", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-13", "reviewer": "Codex", "evidence_base_note": "56 primary reports; literature cutoff 2026-10-13; source examination UTC date 2026-10-13; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Entrez, separately logged public original-body retrieval, and Consensus Pro browser searches. Provider output retained as observed browser text with citation-link mappings, or as previously exported connector documents where present. AI synthesis is not primary full-text verification. Consensus retrieved/included counts are not examined-primary counts. Scite monthly limit was reached earlier in this session; no new Scite query or incoming citation-context audit is claimed for these cases. Tool receipts record actual use. Supplementary discovery outputs do not earn primary-count credit. No independent blinded review.", "skill_version": "5.3", "validator_run": "PASS: exact archived HSEF v5.3 validator rerun after final sealing.", "validator_warnings_addressed": "No warnings.", "limits": "Bounded source-based critical review; no complete-paper/supplement audit, independent scientific peer review or blinded calibration. Revision cases retain original prose outside the three framework output blocks and have explicit correction logs." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "These topic families were selected from an editorial traffic-priority list. Selection was visible; no blind calibration or predetermined clinical verdict was preregistered." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "Human receptor blockade, pharmacological comparators, controlled injury experiments and indication-specific clinical trials were considered. No same-scope human genetics, natural experiment, withdrawal/rechallenge or independent causal-class set establishes the exact combination recovery benefit. Multiple peptide trials do not become independent causal lines solely through different molecules or sponsors." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "Human receptor blockade, pharmacological comparators, controlled injury experiments and indication-specific clinical trials were considered. No same-scope human genetics, natural experiment, withdrawal/rechallenge or independent causal-class set establishes the exact combination recovery benefit. Multiple peptide trials do not become independent causal lines solely through different molecules or sponsors." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "Human receptor blockade, pharmacological comparators, controlled injury experiments and indication-specific clinical trials were considered. No same-scope human genetics, natural experiment, withdrawal/rechallenge or independent causal-class set establishes the exact combination recovery benefit. Multiple peptide trials do not become independent causal lines solely through different molecules or sponsors." }, { "kind": "withdrawal_rechallenge", "available": false, "why_not_sufficient": "Human receptor blockade, pharmacological comparators, controlled injury experiments and indication-specific clinical trials were considered. No same-scope human genetics, natural experiment, withdrawal/rechallenge or independent causal-class set establishes the exact combination recovery benefit. Multiple peptide trials do not become independent causal lines solely through different molecules or sponsors." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": false, "why_not_sufficient": "Human receptor blockade, pharmacological comparators, controlled injury experiments and indication-specific clinical trials were considered. No same-scope human genetics, natural experiment, withdrawal/rechallenge or independent causal-class set establishes the exact combination recovery benefit. Multiple peptide trials do not become independent causal lines solely through different molecules or sponsors." } ], "convergence_present": false, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 56, "claims_total": 61, "claims_verified": 61, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 56, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "CJC-1295 alone increased GH and IGF-I for days in two placebo-controlled ascending-dose trials in healthy adults; no serious adverse reactions were reported over 28-49 days. No combined ipamorelin arm or functional recovery endpoint was measured; short monitored tolerability does not establish chronic stack benefit or safety.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC4" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C2", "text": "CJC-1295 in healthy men increased trough and mean GH and IGF-I while preserving pulsatility after one week. Endocrine dynamics are target engagement rather than recovery; no exact combination or functional comparison was tested.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C3", "text": "A blinded placebo-controlled phase 2 intravenous ipamorelin study randomized 117 bowel-resection patients; the key meal-tolerance endpoint and secondary efficacy analyses showed no significant differences. Postoperative ileus, intravenous single-agent dosing and seven-day exposure differ from healthy-adult injectable stacks; nonsignificance does not prove exact equality or refute all doses.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C4", "text": "Dose-escalation intravenous ipamorelin in healthy male volunteers produced a single GH episode and supported a pharmacokinetic-pharmacodynamic model. A hormone response and modeled potency do not show physical recovery, combination efficacy or chronic subcutaneous safety.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C5", "text": "Intraperitoneal full-length thymosin beta 4 increased fracture-callus force to failure and stiffness after fibular osteotomy in mice. This is another molecule in one injury model and species; TB-500 product equivalence and CJC-ipamorelin recovery are not established.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C6", "text": "A blinded dose-escalation trial randomized 73 venous-ulcer patients to topical full-length thymosin beta 4 or placebo; abstract findings suggest wound-healing potential at 0.03 percent and acceptable short-term tolerability. The abstract does not supply a decisive between-arm efficacy contrast; compression care, formulation, indication and topical route block inference to healthy-adult peptide stacks.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C7", "text": "Local thymosin beta 4 in rat incisions improved collagen organization and wound narrowing without loss of breaking strength. Histological organization and local rat repair do not establish injected TB-500 or combined human secretagogue recovery.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C8", "text": "Topical recombinant thymosin beta 4 in 60 rats changed laminin 5 expression and accelerated full-thickness wound closure at selected doses and times. Wound contractions, model, route and dose-specific effects constrain translation; the marketed exact combination was absent.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C9", "text": "Capromorelin in 395 older adults with mild functional limitation increased IGF-I and lean mass; pooled active groups improved tandem walk at six months and stair climb at 12 months, with glycemic and other adverse signals. The trial stopped early under predefined effect criteria; pooled outcomes, another oral molecule, baseline limitation and longer horizon do not validate healthy-adult CJC-ipamorelin stacks.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C10", "text": "A randomized-order 10-man hormone crossover study found selected balance, walking and stair changes, increased fat-free mass with combined GH plus testosterone, and no strength or flexibility change. Comparisons against baseline, short exposure, small sample and different hormone combination limit placebo-controlled stack inference; mass and muscle gene expression are not uniform functional recovery.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C11", "text": "A three-year open continuation in 10 GH-deficient adults maintained improved muscle volume and improved exercise capacity and strength compared with the original placebo period. Replacement of diagnosed deficiency lies outside the registered population; the uncontrolled continuation cannot establish healthy-adult stack enhancement.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C12", "text": "A 38-person tesamorelin analysis characterized repeated-dose pharmacokinetics in healthy subjects and HIV-infected patients. Pharmacokinetic modeling of another GHRH analogue is not physical recovery, component synergy or clinical safety evidence for the exact stack.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C13", "text": "A 61-person blinded TH 9507 trial in HIV-related central adiposity raised IGF-I, reduced trunk fat at the higher dose and improved selected lipid measures; visceral-fat reduction was not significant. Indication-specific adiposity and metabolic endpoints of another molecule do not establish physical recovery or universal stack net benefit.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C14", "text": "Tesamorelin in 50 HIV-infected adults with abdominal fat reduced visceral and liver fat versus placebo over six months; transient fasting-glucose increase was observed at two weeks. Different molecule and indication; adiposity endpoints and transient glycemic changes do not establish CJC-ipamorelin functional recovery or clinical net benefit.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 1:Methods:paragraph6, 2:Results:paragraph3, 2:Results:paragraph4, 2:Results:paragraph5, 2:Results:paragraph12. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C15", "text": "A secondary analysis of the 50-person tesamorelin liver-fat trial associated falling FGF 21 with liver-fat and biochemical changes; the treatment contrast for FGF 21 was only a trend. Same-study secondary associations do not identify mediation or add an independent trial; liver-fat indication is outside healthy-adult recovery.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C16", "text": "Randomized GH infusion in eight healthy men promoted lipolysis and reduced clamp insulin sensitivity by approximately half, with reduced active pyruvate dehydrogenase. Acute pharmacological GH infusion establishes a metabolic risk mechanism, not the chronic adverse-event rate of an untested secretagogue combination.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C17", "text": "In eight healthy men receiving GH infusion, ketone infusion suppressed free fatty acids and improved glucose disposal compared with saline. This mechanistic rescue suggests context dependence of GH-related insulin resistance; it does not establish a safe clinical peptide stack or recovery benefit.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C18", "text": "A placebo-controlled GH-receptor antagonist trial in twenty healthy men shortened prolonged-exercise time to exhaustion without changing VO2 max. Physiological GH contribution under receptor blockade does not prove benefit from supraphysiological stimulation or the exact peptide combination.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C19", "text": "Local GH infusion in seven healthy men increased forearm amino-acid uptake consistent with acute muscle protein synthesis. A short regional tracer response does not demonstrate stronger muscle, healing or lasting physical recovery.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C20", "text": "Six-week nightly GHRH treatment in eleven older men increased GH and selected strength/endurance measures but not IGF-I, body composition or muscle-energy measures. An uncontrolled before-after study of another formulation is vulnerable to practice effects and multiple outcomes; it cannot establish placebo-controlled stack benefit.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C21", "text": "Blinded GH versus placebo in thirty-three older hip-replacement patients improved postoperative four-minute walking distance and selected muscle preservation; most recipients had dose-related side effects. Perioperative GH and underlying osteoarthritis differ from healthy-adult secretagogue stacks; selective strength findings and small sample limit generalization.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C22", "text": "A nine-man blinded crossover trial found GH-induced insulin resistance, including with concomitant acipimox, and increased muscle triglyceride content. Physiological mechanism and pharmacological dose are relevant boundaries, not quantified chronic exact-stack harm.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C23", "text": "A twelve-person blinded crossover GH trial in HIV-associated wasting improved peripheral oxygen extraction during exercise. Disease wasting, recombinant GH and oxygen-extraction physiology cannot validate recovery enhancement in nondeficient healthy adults.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C24", "text": "A nine-person randomized GH-infusion crossover increased mitochondrial oxidative capacity and whole-body protein synthesis, with glucose, insulin and fatty-acid changes. Mitochondrial and tracer endpoints are biomarkers; there was no functional recovery measurement or exact combination.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C25", "text": "MK-677 in eight calorically restricted healthy adults improved nitrogen balance and GH/IGF-I over seven treatment days versus placebo. Diet-induced nitrogen wasting is a short metabolic endpoint, not strength or return to activity; another oral molecule cannot establish stack efficacy.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C26", "text": "The two ROMANA trials randomized 979 lung-cancer cachexia patients; anamorelin increased lean mass but did not improve co-primary handgrip strength, with some severe hyperglycemia. Cancer cachexia and a different oral ghrelin agonist are outside the nominal population; null handgrip is a mass-versus-function boundary rather than proof all axis stimulation fails.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C27", "text": "A 203-person open randomized gastric-cancer cachexia trial did not meet its primary between-arm lean-mass endpoint at eight weeks; hyperglycemia occurred in the active arm. Modified per-protocol analysis, no placebo blinding and another disease-specific drug constrain inference; a nonsignificant trend is not established benefit.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C28", "text": "Mass-spectrometric testing identified altered GH and glycine-extended GHRP-2, GHRP-6 and ipamorelin in black-market growth products, with synthetic confirmation of selected identities. Analytical identity evidence from sampled products cannot estimate market-wide adulteration prevalence or clinical efficacy and harms.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C29", "text": "A post hoc ROMANA analysis of 795 patients associated greater clinical improvements with selected baseline inflammation and wasting groups, including subgroup handgrip findings. This is the same parent trials and post hoc subgroup analysis; it does not erase the null co-primary handgrip results or create a new independent functional trial.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C30", "text": "Two small blinded healthy-adult phase 1 anamorelin studies increased hunger and, at selected doses, caloric intake. Appetite effects show a possible non-GH route to weight gain; they are not recovery, stack synergy or proof that increased mass means improved function.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3", "SC4" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C31", "text": "A retrospectively selected fourteen-man testosterone-treated cohort receiving GHRP-2/GHRP-6/sermorelin showed increased IGF-I. Only fourteen of 105 met compliance criteria, co-treatments varied, and no credible control or physical outcome was measured; another triple combination does not validate CJC-ipamorelin.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C32", "text": "Ipamorelin stimulated GH in rat pituitary cells, rats and swine; antagonist profiling supported a GHRP-like receptor and comparatively selective hormonal effects in swine. Preclinical selectivity and acute GH release do not establish healthy-adult recovery or long-term combination safety.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C33", "text": "Ipamorelin increased longitudinal bone growth and body-weight gain over fifteen days in adult female rats, without measured total IGF-I change. Rat longitudinal growth is not adult human injury recovery; species, growth physiology and formulation boundaries remain.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C34", "text": "CJC-1295-associated serum proteomic changes in eleven healthy men supplied candidate markers of GH/IGF-I activity. Before-after protein spots and correlations do not measure recovery or isolate mediation; participant overlap with the parent CJC pulsatility work must be grouped.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:2. Materials and Methods:paragraph0, 1:2. Materials and Methods:paragraph1, 1:2. Materials and Methods:paragraph13, 2:3. Results:paragraph2, 2:3. Results:paragraph3, 2:3. Results:paragraph4. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C35", "text": "Ipamorelin increased adiposity and food intake in GH-intact and GH-deficient mice, indicating GH-independent actions differing from GH itself. Mouse adiposity does not establish a human harm rate; it challenges assuming every secretagogue effect is explained by the GH axis.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3", "SC4" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C36", "text": "Intravenous ipamorelin improved selected bowel-transit and, with repeated dosing, output and intake measures in a rat postoperative-ileus model. Rodent gastrointestinal recovery did not translate to the primary human ipamorelin meal-tolerance result; healthy-adult muscular recovery was not tested.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C37", "text": "Mass spectrometry identified a twenty-nine-amino-acid peptide marketed as CJC-1295 in an unknown pharmaceutical preparation. A market label and a sequence are insufficient evidence of equivalence to the long-acting albumin-binding clinical formulation or of efficacy, purity and safety across products.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C38", "text": "Ipamorelin improved postoperative gastric emptying in rats and rescued contractile responses in isolated gastric tissue. Single-agent animal motility does not establish a healthy-adult stack or overcome the human ileus trial's null efficacy result.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C39", "text": "Mouse acute-injury and hemorrhage models showed rapidly impaired hepatic GH signaling and altered receptor features despite GH challenge. A signaling-resistance model does not establish clinical recovery benefit or justify increasing doses; injured physiology differs from healthy adults.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC4" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C40", "text": "GHRP-6 prevented hypertrophic scarring in a rabbit model but did not significantly reverse established scars. Another peptide, local route and stage-specific injury model are not direct CJC-ipamorelin clinical evidence; early proteomics do not prove the causal mediator.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C41", "text": "A pediatric severe-burn report combining randomized and matched comparisons found similar mortality but greater hyperglycemia and insulin requirements with GH. Retrospective aggregation, mixed controls and pediatric burn indication prevent extrapolating reported safety to critically ill adults or healthy-adult peptide stacks.", "carries_number": false, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C42", "text": "Topical GH accelerated wound closure and selected repair histology in mice compared with vehicle. Local GH in one skin-wound species does not demonstrate injected secretagogue stack benefit or endogenous necessity.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C43", "text": "A small comparative burn series reported better wound healing and other clinical measures with GH plus conservative care, alongside metabolic adverse changes. Thirteen treated and nine control patients with nonrandomized allocation cannot establish a reliable mortality benefit or general healthy-adult recovery effect.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C44", "text": "Randomized rat rotator-cuff repair experiments found no benefit of postoperative GH and worse ultimate failure load with prolonged high-dose perioperative GH. The harm is specific to an animal tendon-bone injury and high dosing; it does not prove every human peptide formulation harms tendons.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C45", "text": "Injured mouse muscle increased thymosin beta 4 expression, and peptide forms increased myoblast chemotaxis and cell-culture wound closure. Expression and cellular migration do not establish endogenous necessity, full in-vivo muscle recovery or human injected peptide efficacy.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C46", "text": "A thirty-two-rat Achilles repair study found a significant mechanical advantage for TB-500 alone; combined BPC-157/TB-500 did not confer additional benefit over individual treatment. This recent four-arm animal experiment tests another exact stack, not CJC-ipamorelin; small groups and four-week surgical model do not establish human efficacy, safety or dose equivalence.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C47", "text": "Topical or intraperitoneal full-length thymosin beta 4 improved rat skin reepithelialization and contraction, with increased collagen and angiogenesis. Rat skin closure and cultured keratinocyte migration do not establish marketed TB-500 identity or healthy-adult CJC-ipamorelin recovery.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C48", "text": "Local thymosin beta 4 in fibrin sealant improved four-week rat medial-collateral-ligament histology and biomechanical properties. Local delivery, animal injury and another molecule limit translation; it is not a controlled human stack or proof of systemic safety.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C49", "text": "Thymosinbeta 4 enhanced rat palatal-wound closure and primary-cell migration, with MMP 2 and VEGF changes. Small animal and cell assays show partial repair support, not a human functional recovery or exact-stack clinical outcome.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C50", "text": "An originally produced recombinant human thymosin beta 4 preparation promoted full-thickness wound healing in mice. Recombinant expression was a production method, not endogenous necessity; product, route and animal scope prevent clinical stack inference.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C51", "text": "A blinded 65-person MK-677 trial increased GH, IGF-I and fat-free mass over twelve months but showed no significant strength or function improvement; glucose rose and insulin sensitivity fell. Primary power focused on fat-free mass and visceral fat; secondary functional nulls do not establish equivalence, and another oral agent and older population do not test the exact stack.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3", "SC4" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph1, 1:METHODS:paragraph10, 1:METHODS:paragraph11, 1:METHODS:paragraph18, 1:METHODS:paragraph19, 2:RESULTS:paragraph4, 2:RESULTS:paragraph5, 2:RESULTS:paragraph15, 2:RESULTS:paragraph16, 2:RESULTS:paragraph20, 2:RESULTS:paragraph21. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C52", "text": "A blinded ninety-six-athlete trial found an approximately 3.9 percent GH-associated sprint-capacity increase over eight weeks, with no significant strength, aerobic endurance or jump-power change; lean-mass gain largely reflected extracellular water. Different hormones and a performance endpoint do not test exact peptide recovery; sprint gain was not maintained after six-week washout, and athletic importance and safety were uncertain.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C53", "text": "In sixteen young men randomized to identical resistance training with GH or placebo, GH increased fat-free mass and whole-body synthesis but did not add muscle-strength or quadriceps-synthesis gain over twelve weeks. Small trial and recombinant GH differ from the exact stack; similar training gains do not prove all GH-axis exposures ineffective or establish equivalence.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C54", "text": "In twenty-three older men assigned to the same resistance training with GH or placebo, fat-free mass and water rose more with GH but muscle protein synthesis and strength increments were similar. The trial supplies a proxy-versus-function and concurrent-training boundary; another molecule and small unequal groups do not test exact-combination recovery.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C55", "text": "Two blinded trials in 532 critically ill adults found higher mortality with high-dose GH: 39 versus 20 percent and 44 versus 18 percent; survivors also had longer ventilation and stays. This is a serious randomized safety boundary for high-dose GH in prolonged critical illness, not a measured mortality rate for healthy-adult CJC-ipamorelin stacks.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C56", "text": "A blinded 131-person older-adult factorial GH/sex-steroid trial increased lean mass; combined GH-testosterone improved men's VO2 max, while women's strength/endurance were not significantly improved and metabolic or edema-related adverse events were frequent. Different hormone combination, sex-specific responses and 26-week exposure do not establish exact-stack recovery; lean mass alone and correlational changes do not identify mediation.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC1", "text": "Controlled human CJC-1295 and ipamorelin reports establish single-agent GH-axis activity. For the recovery mechanism, these are endocrine biomarkers; the exact combination has no verified human functional result in this search. The biomarker cap is applied to inference from target engagement to recovery, not a denial that pharmacodynamic stimulation occurred.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 1, 2, 4, 12, 15, 16, 17, 18, 19, 20, 22, 24, 25, 30, 31, 32, 33, 34, 35, 39, 51 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC2", "text": "Partial biological support comes from single-agent human pharmacodynamics and related repair experiments. No examined report directly demonstrates a positive functional recovery effect of the exact CJC-1295 plus ipamorelin combination in the registered population. Different hormones, molecules, disease indications and animal injuries do not cross its clinical Δ threshold.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 2, 3, 4, 9, 10, 11, 18, 19, 20, 21, 23, 24, 25, 26, 27, 29, 31, 32, 33, 34, 36, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC3", "text": "The claim that component evidence establishes all marketed stack benefits remains an unsupported generalization. The new BPC-157/TB-500 four-arm rat study supplies a useful counterexample to automatic additivity, while its own positive single-agent mechanical result retains its rat scope. Approved or studied single-agent indications remain distinct.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 20, 21, 23, 25, 26, 27, 28, 29, 30, 31, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC4", "text": "A broad net-benefit claim across promoted healthy-adult uses has no verified exact-stack controlled benefit-harm comparison. Short CJC tolerability, ipamorelin ileus monitoring, GH-axis metabolic risks and sampled product-identity problems cannot be combined into a measured exact-stack net benefit or universal toxicity conclusion.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 1, 3, 6, 9, 10, 11, 13, 14, 16, 17, 21, 22, 26, 27, 28, 30, 35, 37, 39, 41, 43, 44, 46, 51, 52, 55, 56 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CH", "text": "CJC-1295 and ipamorelin can stimulate GH, but the marketed combination has no verified human physical-recovery benefit in this bounded review.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 4, 3, 51, 46 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-13", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "Teichman SL, Neale A, Lawrence B et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism. 2006.", "tier": "A", "kind": "rct", "pmid": "16352683", "doi": "10.1210/jc.2005-1536", "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16352683", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC1", "CSC2", "CSC4", "CH" ] }, { "n": 2, "citation": "Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism. 2006.", "tier": "A", "kind": "primary", "pmid": "17018654", "doi": "10.1210/jc.2006-1702", "url": "https://pubmed.ncbi.nlm.nih.gov/17018654/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "CJC-pulsatility-cohort", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC1", "CSC2" ] }, { "n": 3, "citation": "Beck DE, Sweeney WB, McCarter MD et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease. 2014.", "tier": "A", "kind": "rct", "pmid": "25331030", "doi": "10.1007/s00384-014-2030-8", "url": "https://pubmed.ncbi.nlm.nih.gov/25331030/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25331030", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC2", "CSC3", "CSC4", "CH" ] }, { "n": 4, "citation": "Gobburu JV, Agersø H, Jusko WJ et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research. 1999.", "tier": "A", "kind": "rct", "pmid": "10496658", "doi": "10.1023/a:1018955126402", "url": "https://pubmed.ncbi.nlm.nih.gov/10496658/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10496658", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC1", "CSC2", "CH" ] }, { "n": 5, "citation": "Brady RD, Grills BL, Schuijers JA et al. Thymosin β4 administration enhances fracture healing in mice. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2014.", "tier": "A", "kind": "primary", "pmid": "25042765", "doi": "10.1002/jor.22686", "url": "https://pubmed.ncbi.nlm.nih.gov/25042765/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25042765", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC3" ] }, { "n": 6, "citation": "Guarnera G, DeRosa A, Camerini R et al. The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences. 2010.", "tier": "A", "kind": "rct", "pmid": "20536470", "doi": "10.1111/j.1749-6632.2010.05490.x", "url": "https://pubmed.ncbi.nlm.nih.gov/20536470/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20536470", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC3", "CSC4" ] }, { "n": 7, "citation": "Ehrlich HP, Hazard SW. Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts. Annals of the New York Academy of Sciences. 2010.", "tier": "A", "kind": "primary", "pmid": "20536458", "doi": "10.1111/j.1749-6632.2010.05483.x", "url": "https://pubmed.ncbi.nlm.nih.gov/20536458/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20536458", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC3" ] }, { "n": 8, "citation": "Li Y, Wang G, Yu H et al. [Expression of laminin 5 in rat skin wounds regulated by recombinant thymosin beta4]. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery. 2008.", "tier": "A", "kind": "primary", "pmid": "19068595", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19068595/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19068595", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC3" ] }, { "n": 9, "citation": "White HK, Petrie CD, Landschulz W et al. Effects of an oral growth hormone secretagogue in older adults. The Journal of clinical endocrinology and metabolism. 2009.", "tier": "A", "kind": "rct", "pmid": "19174493", "doi": "10.1210/jc.2008-0632", "url": "https://pubmed.ncbi.nlm.nih.gov/19174493/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19174493", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC2", "CSC3", "CSC4" ] }, { "n": 10, "citation": "Brill KT, Weltman AL, Gentili A et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. The Journal of clinical endocrinology and metabolism. 2002.", "tier": "A", "kind": "rct", "pmid": "12466367", "doi": "10.1210/jc.2002-020098", "url": "https://pubmed.ncbi.nlm.nih.gov/12466367/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID12466367", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC2", "CSC3", "CSC4" ] }, { "n": 11, "citation": "Jørgensen JO, Thuesen L, Müller J et al. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. European journal of endocrinology. 1994.", "tier": "A", "kind": "rct", "pmid": "8156094", "doi": "10.1530/eje.0.1300224", "url": "https://pubmed.ncbi.nlm.nih.gov/8156094/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID8156094", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC2", "CSC3", "CSC4" ] }, { "n": 12, "citation": "González-Sales M, Barrière O, Tremblay PO et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clinical pharmacokinetics. 2015.", "tier": "A", "kind": "rct", "pmid": "25358450", "doi": "10.1007/s40262-014-0202-x", "url": "https://pubmed.ncbi.nlm.nih.gov/25358450/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25358450", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC1", "CSC3" ] }, { "n": 13, "citation": "Falutz J, Allas S, Kotler D et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS (London, England). 2005.", "tier": "A", "kind": "rct", "pmid": "16052083", "doi": "10.1097/01.aids.0000180099.35146.30", "url": "https://pubmed.ncbi.nlm.nih.gov/16052083/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16052083", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC3", "CSC4" ] }, { "n": 14, "citation": "Stanley TL, Feldpausch MN, Oh J et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014 Jul 23-30.", "tier": "A", "kind": "rct", "pmid": "25038357", "doi": "10.1001/jama.2014.8334", "url": "https://pubmed.ncbi.nlm.nih.gov/25038357/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "NCT01263717", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 1:Methods:paragraph6, 2:Results:paragraph3, 2:Results:paragraph4, 2:Results:paragraph5, 2:Results:paragraph12. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC3", "CSC4" ] }, { "n": 15, "citation": "Braun LR, Feldpausch MN, Czerwonka N et al. Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2017.", "tier": "A", "kind": "rct", "pmid": "29031905", "doi": "10.1016/j.ghir.2017.10.002", "url": "https://pubmed.ncbi.nlm.nih.gov/29031905/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "NCT01263717", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC1", "CSC3" ] }, { "n": 16, "citation": "Nellemann B, Vendelbo MH, Nielsen TS et al. Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. Acta physiologica (Oxford, England). 2014.", "tier": "A", "kind": "rct", "pmid": "24148194", "doi": "10.1111/apha.12183", "url": "https://pubmed.ncbi.nlm.nih.gov/24148194/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24148194", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC1", "CSC4" ] }, { "n": 17, "citation": "Høgild ML, Hjelholt AJ, Hansen J et al. Ketone Body Infusion Abrogates Growth Hormone-Induced Lipolysis and Insulin Resistance. The Journal of clinical endocrinology and metabolism. 2023.", "tier": "A", "kind": "rct", "pmid": "36240323", "doi": "10.1210/clinem/dgac595", "url": "https://pubmed.ncbi.nlm.nih.gov/36240323/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36240323", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC1", "CSC4" ] }, { "n": 18, "citation": "Goto K, Doessing S, Nielsen RH et al. Growth hormone receptor antagonist treatment reduces exercise performance in young males. The Journal of clinical endocrinology and metabolism. 2009.", "tier": "A", "kind": "rct", "pmid": "19549743", "doi": "10.1210/jc.2009-0407", "url": "https://pubmed.ncbi.nlm.nih.gov/19549743/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19549743", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC1", "CSC2", "CSC3" ] }, { "n": 19, "citation": "Fryburg DA, Gelfand RA, Barrett EJ. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. The American journal of physiology. 1991.", "tier": "A", "kind": "primary", "pmid": "2003602", "doi": "10.1152/ajpendo.1991.260.3.E499", "url": "https://pubmed.ncbi.nlm.nih.gov/2003602/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID2003602", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC1", "CSC2" ] }, { "n": 20, "citation": "Vittone J, Blackman MR, Busby-Whitehead J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism: clinical and experimental. 1997.", "tier": "A", "kind": "primary", "pmid": "9005976", "doi": "10.1016/s0026-0495(97)90174-8", "url": "https://pubmed.ncbi.nlm.nih.gov/9005976/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9005976", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC1", "CSC2", "CSC3" ] }, { "n": 21, "citation": "Weissberger AJ, Anastasiadis AD, Sturgess I et al. Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement. Clinical endocrinology. 2003.", "tier": "A", "kind": "rct", "pmid": "12519419", "doi": "10.1046/j.1365-2265.2003.01700.x", "url": "https://pubmed.ncbi.nlm.nih.gov/12519419/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID12519419", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC2", "CSC3", "CSC4" ] }, { "n": 22, "citation": "Krag MB, Gormsen LC, Guo Z et al. Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics. American journal of physiology. Endocrinology and metabolism. 2007.", "tier": "A", "kind": "rct", "pmid": "17132823", "doi": "10.1152/ajpendo.00374.2006", "url": "https://pubmed.ncbi.nlm.nih.gov/17132823/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID17132823", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC1", "CSC4" ] }, { "n": 23, "citation": "Esposito JG, Thomas SG, Kingdon L et al. Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. The Journal of clinical endocrinology and metabolism. 2004.", "tier": "A", "kind": "rct", "pmid": "15472216", "doi": "10.1210/jc.2004-0451", "url": "https://pubmed.ncbi.nlm.nih.gov/15472216/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID15472216", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC2", "CSC3" ] }, { "n": 24, "citation": "Short KR, Moller N, Bigelow ML et al. Enhancement of muscle mitochondrial function by growth hormone. The Journal of clinical endocrinology and metabolism. 2008.", "tier": "A", "kind": "rct", "pmid": "18000087", "doi": "10.1210/jc.2007-1814", "url": "https://pubmed.ncbi.nlm.nih.gov/18000087/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18000087", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC1", "CSC2" ] }, { "n": 25, "citation": "Murphy MG, Plunkett LM, Gertz BJ et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism. 1998.", "tier": "A", "kind": "rct", "pmid": "9467534", "doi": "10.1210/jcem.83.2.4551", "url": "https://pubmed.ncbi.nlm.nih.gov/9467534/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9467534", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC1", "CSC2", "CSC3" ] }, { "n": 26, "citation": "Temel JS, Abernethy AP, Currow DC et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. The Lancet. Oncology. 2016.", "tier": "A", "kind": "rct", "pmid": "26906526", "doi": "10.1016/S1470-2045(15)00558-6", "url": "https://pubmed.ncbi.nlm.nih.gov/26906526/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "ROMANA1-and-ROMANA2", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC2", "CSC3", "CSC4" ] }, { "n": 27, "citation": "Yamamoto K, Kurokawa Y, Miyazaki Y et al. Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial. EClinicalMedicine. 2025.", "tier": "A", "kind": "primary", "pmid": "41181834", "doi": "10.1016/j.eclinm.2025.103500", "url": "https://pubmed.ncbi.nlm.nih.gov/41181834/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41181834", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC2", "CSC3", "CSC4" ] }, { "n": 28, "citation": "Krug O, Thomas A, Malerød-Fjeld H et al. Analysis of new growth promoting black market products. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2018.", "tier": "A", "kind": "primary", "pmid": "29864719", "doi": "10.1016/j.ghir.2018.05.001", "url": "https://pubmed.ncbi.nlm.nih.gov/29864719/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29864719", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC3", "CSC4" ] }, { "n": 29, "citation": "Laird BJA, Skipworth R, Bonomi PD et al. Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2. Journal of cachexia, sarcopenia and muscle. 2025.", "tier": "A", "kind": "rct", "pmid": "39992021", "doi": "10.1002/jcsm.13732", "url": "https://pubmed.ncbi.nlm.nih.gov/39992021/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "ROMANA1-and-ROMANA2", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC2", "CSC3" ] }, { "n": 30, "citation": "Blum RA, Mair S, Duus EM. Appetite and food intake results from phase I studies of anamorelin. Journal of cachexia, sarcopenia and muscle. 2019.", "tier": "A", "kind": "rct", "pmid": "31074178", "doi": "10.1002/jcsm.12439", "url": "https://pubmed.ncbi.nlm.nih.gov/31074178/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID31074178", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC1", "CSC3", "CSC4" ] }, { "n": 31, "citation": "Sigalos JT, Pastuszak AW, Allison A et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. American journal of men's health. 2017.", "tier": "A", "kind": "primary", "pmid": "28830317", "doi": "10.1177/1557988317718662", "url": "https://pubmed.ncbi.nlm.nih.gov/28830317/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28830317", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC1", "CSC2", "CSC3" ] }, { "n": 32, "citation": "Raun K, Hansen BS, Johansen NL et al. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. 1998.", "tier": "A", "kind": "primary", "pmid": "9849822", "doi": "10.1530/eje.0.1390552", "url": "https://pubmed.ncbi.nlm.nih.gov/9849822/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9849822", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC1", "CSC2" ] }, { "n": 33, "citation": "Johansen PB, Nowak J, Skjaerbaek C et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1999.", "tier": "A", "kind": "primary", "pmid": "10373343", "doi": "10.1054/ghir.1999.9998", "url": "https://pubmed.ncbi.nlm.nih.gov/10373343/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10373343", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC1", "CSC2" ] }, { "n": 34, "citation": "Sackmann-Sala L, Ding J, Frohman LA et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2009.", "tier": "A", "kind": "primary", "pmid": "19386527", "doi": "10.1016/j.ghir.2009.03.001", "url": "https://pubmed.ncbi.nlm.nih.gov/19386527/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "CJC-pulsatility-cohort", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:2. Materials and Methods:paragraph0, 1:2. Materials and Methods:paragraph1, 1:2. Materials and Methods:paragraph13, 2:3. Results:paragraph2, 2:3. Results:paragraph3, 2:3. Results:paragraph4. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC1", "CSC2" ] }, { "n": 35, "citation": "Lall S, Tung LY, Ohlsson C et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications. 2001.", "tier": "A", "kind": "primary", "pmid": "11162489", "doi": "10.1006/bbrc.2000.4065", "url": "https://pubmed.ncbi.nlm.nih.gov/11162489/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID11162489", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC1", "CSC3", "CSC4" ] }, { "n": 36, "citation": "Venkova K, Mann W, Nelson R et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics. 2009.", "tier": "A", "kind": "primary", "pmid": "19289567", "doi": "10.1124/jpet.108.149211", "url": "https://pubmed.ncbi.nlm.nih.gov/19289567/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19289567", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC2", "CSC3" ] }, { "n": 37, "citation": "Henninge J, Pepaj M, Hullstein I et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis. 2010.", "tier": "A", "kind": "primary", "pmid": "21204297", "doi": "10.1002/dta.233", "url": "https://pubmed.ncbi.nlm.nih.gov/21204297/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID21204297", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC3", "CSC4" ] }, { "n": 38, "citation": "Greenwood-Van Meerveld B, Tyler K, Mohammadi E et al. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology. 2012.", "tier": "A", "kind": "primary", "pmid": "27186127", "doi": "10.2147/JEP.S35396", "url": "https://pubmed.ncbi.nlm.nih.gov/27186127/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID27186127", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC2", "CSC3" ] }, { "n": 39, "citation": "Corrick RM, Li L, Frank SJ et al. Hepatic growth hormone resistance after acute injury. Endocrinology. 2013.", "tier": "A", "kind": "primary", "pmid": "23417424", "doi": "10.1210/en.2012-2134", "url": "https://pubmed.ncbi.nlm.nih.gov/23417424/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23417424", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC1", "CSC2", "CSC4" ] }, { "n": 40, "citation": "Fernández-Mayola M, Betancourt L, Molina-Kautzman A et al. Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study. International wound journal. 2018.", "tier": "A", "kind": "primary", "pmid": "29464859", "doi": "10.1111/iwj.12895", "url": "https://pubmed.ncbi.nlm.nih.gov/29464859/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29464859", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC2", "CSC3" ] }, { "n": 41, "citation": "Ramirez RJ, Wolf SE, Barrow RE et al. Growth hormone treatment in pediatric burns: a safe therapeutic approach. Annals of surgery. 1998.", "tier": "A", "kind": "rct", "pmid": "9790334", "doi": "10.1097/00000658-199810000-00001", "url": "https://pubmed.ncbi.nlm.nih.gov/9790334/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9790334", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC3", "CSC4" ] }, { "n": 42, "citation": "Messias de Lima CF, de Araújo Vieira LF, de Carvalho Wanderley LA et al. Topical Growth Hormone Accelerates Wound Healing in Mice. Wounds : a compendium of clinical research and practice. 2017.", "tier": "A", "kind": "primary", "pmid": "28976342", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/28976342/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28976342", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC2", "CSC3" ] }, { "n": 43, "citation": "Singh KP, Prasad R, Chari PS et al. Effect of growth hormone therapy in burn patients on conservative treatment. Burns : journal of the International Society for Burn Injuries. 1998.", "tier": "A", "kind": "primary", "pmid": "9915674", "doi": "10.1016/s0305-4179(98)00113-2", "url": "https://pubmed.ncbi.nlm.nih.gov/9915674/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID9915674", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC2", "CSC3", "CSC4" ] }, { "n": 44, "citation": "Baumgarten KM, Oliver HA, Foley J et al. Human growth hormone may be detrimental when used to accelerate recovery from acute tendon-bone interface injuries. The Journal of bone and joint surgery. American volume. 2013.", "tier": "A", "kind": "primary", "pmid": "23636184", "doi": "10.2106/JBJS.L.00222", "url": "https://pubmed.ncbi.nlm.nih.gov/23636184/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23636184", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC2", "CSC3", "CSC4" ] }, { "n": 45, "citation": "Tokura Y, Nakayama Y, Fukada S et al. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. Journal of biochemistry. 2011.", "tier": "A", "kind": "primary", "pmid": "20880960", "doi": "10.1093/jb/mvq115", "url": "https://pubmed.ncbi.nlm.nih.gov/20880960/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20880960", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC2", "CSC3" ] }, { "n": 46, "citation": "Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery. 2026.", "tier": "A", "kind": "primary", "pmid": "42542926", "doi": "10.52312/jdrs.2026.2951", "url": "https://pubmed.ncbi.nlm.nih.gov/42542926/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42542926", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC2", "CSC3", "CSC4", "CH" ] }, { "n": 47, "citation": "Malinda KM, Sidhu GS, Mani H et al. Thymosin beta4 accelerates wound healing. The Journal of investigative dermatology. 1999.", "tier": "A", "kind": "primary", "pmid": "10469335", "doi": "10.1046/j.1523-1747.1999.00708.x", "url": "https://pubmed.ncbi.nlm.nih.gov/10469335/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10469335", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC2", "CSC3" ] }, { "n": 48, "citation": "Xu B, Yang M, Li Z et al. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regulatory peptides. 2013.", "tier": "A", "kind": "primary", "pmid": "23523891", "doi": "10.1016/j.regpep.2013.03.026", "url": "https://pubmed.ncbi.nlm.nih.gov/23523891/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23523891", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC2", "CSC3" ] }, { "n": 49, "citation": "Zhu T, Park HC, Son KM et al. Effects of thymosin β4 on wound healing of rat palatal mucosa. International journal of molecular medicine. 2014.", "tier": "A", "kind": "primary", "pmid": "24993983", "doi": "10.3892/ijmm.2014.1832", "url": "https://pubmed.ncbi.nlm.nih.gov/24993983/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24993983", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC2", "CSC3" ] }, { "n": 50, "citation": "Li X, Zheng L, Peng F et al. Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing. Protein expression and purification. 2007.", "tier": "A", "kind": "primary", "pmid": "17923415", "doi": "10.1016/j.pep.2007.08.011", "url": "https://pubmed.ncbi.nlm.nih.gov/17923415/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID17923415", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC2", "CSC3" ] }, { "n": 51, "citation": "Nass R, Pezzoli SS, Oliveri MC et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of internal medicine. 2008.", "tier": "A", "kind": "rct", "pmid": "18981485", "doi": "10.7326/0003-4819-149-9-200811040-00003", "url": "https://pubmed.ncbi.nlm.nih.gov/18981485/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18981485", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph1, 1:METHODS:paragraph10, 1:METHODS:paragraph11, 1:METHODS:paragraph18, 1:METHODS:paragraph19, 2:RESULTS:paragraph4, 2:RESULTS:paragraph5, 2:RESULTS:paragraph15, 2:RESULTS:paragraph16, 2:RESULTS:paragraph20, 2:RESULTS:paragraph21. No complete-paper or supplement audit claimed.", "carries_claims": [ "C51", "CSC1", "CSC2", "CSC3", "CSC4", "CH" ] }, { "n": 52, "citation": "Meinhardt U, Nelson AE, Hansen JL et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Annals of internal medicine. 2010.", "tier": "A", "kind": "rct", "pmid": "20439575", "doi": "10.7326/0003-4819-152-9-201005040-00007", "url": "https://pubmed.ncbi.nlm.nih.gov/20439575/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20439575", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C52", "CSC2", "CSC3", "CSC4" ] }, { "n": 53, "citation": "Yarasheski KE, Campbell JA, Smith K et al. Effect of growth hormone and resistance exercise on muscle growth in young men. The American journal of physiology. 1992.", "tier": "A", "kind": "rct", "pmid": "1550219", "doi": "10.1152/ajpendo.1992.262.3.E261", "url": "https://pubmed.ncbi.nlm.nih.gov/1550219/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID1550219", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C53", "CSC2", "CSC3" ] }, { "n": 54, "citation": "Yarasheski KE, Zachwieja JJ, Campbell JA et al. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. The American journal of physiology. 1995.", "tier": "A", "kind": "rct", "pmid": "7864103", "doi": "10.1152/ajpendo.1995.268.2.E268", "url": "https://pubmed.ncbi.nlm.nih.gov/7864103/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID7864103", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C54", "CSC2", "CSC3" ] }, { "n": 55, "citation": "Takala J, Ruokonen E, Webster NR et al. Increased mortality associated with growth hormone treatment in critically ill adults. The New England journal of medicine. 1999.", "tier": "A", "kind": "rct", "pmid": "10477776", "doi": "10.1056/NEJM199909093411102", "url": "https://pubmed.ncbi.nlm.nih.gov/10477776/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID10477776", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C55", "CSC3", "CSC4" ] }, { "n": 56, "citation": "Blackman MR, Sorkin JD, Münzer T et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002.", "tier": "A", "kind": "rct", "pmid": "12425705", "doi": "10.1001/jama.288.18.2282", "url": "https://pubmed.ncbi.nlm.nih.gov/12425705/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID12425705", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C56", "CSC2", "CSC3", "CSC4" ] } ], "independence_basis": { "required": false, "lines": [], "shared_failure_mode_checked": true, "note": "All selected reports carry study-unit identifiers. No nominal Γ claim or companion reaches Ζ, so no independent causal lines are claimed. Parent trial reports are grouped conservatively; neighboring clinical comparators cannot create convergence for an untested exact intervention." }, "gamma_hard_rules_considered": [ { "subclaim_id": "SC1", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Triggered for individual rat/mouse/rabbit repair-support inferences; ceiling Γ for transfer to the registered human stack. Separate human comparator trials are not re-capped as animal evidence." }, { "subclaim_id": "SC1", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Triggered for endocrine, tracer, mitochondrial and body-composition-only support offered as physical recovery. Studies with genuine functional endpoints retain their different intervention and indication scope." }, { "subclaim_id": "SC2", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Triggered for individual rat/mouse/rabbit repair-support inferences; ceiling Γ for transfer to the registered human stack. Separate human comparator trials are not re-capped as animal evidence." }, { "subclaim_id": "SC2", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Triggered for endocrine, tracer, mitochondrial and body-composition-only support offered as physical recovery. Studies with genuine functional endpoints retain their different intervention and indication scope." }, { "subclaim_id": "SC3", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Triggered for individual rat/mouse/rabbit repair-support inferences; ceiling Γ for transfer to the registered human stack. Separate human comparator trials are not re-capped as animal evidence." }, { "subclaim_id": "SC3", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Triggered for endocrine, tracer, mitochondrial and body-composition-only support offered as physical recovery. Studies with genuine functional endpoints retain their different intervention and indication scope." }, { "subclaim_id": "SC4", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Triggered for individual rat/mouse/rabbit repair-support inferences; ceiling Γ for transfer to the registered human stack. Separate human comparator trials are not re-capped as animal evidence." }, { "subclaim_id": "SC4", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Triggered for endocrine, tracer, mitochondrial and body-composition-only support offered as physical recovery. Studies with genuine functional endpoints retain their different intervention and indication scope." } ], "consensus_validation": { "completed": true, "status": "completed_original_source_reconciliation", "provider_mode": "Authenticated Consensus Deep research connector; completed provider output retained privately; original-source access checked separately", "queries": [ "https://consensus.app/search/for-an-exhaustive-primary-literature-review-suppor/ITFmNdOOQjKS8-DTEgyHgQ/" ], "query_record_note": "Exact provider question/response retained privately in its retrieval receipt.", "primary_comparison_count": 10, "primary_comparisons": [ { "pmid": "16352683", "doi": "10.1210/jc.2005-1536", "source_type": "primary study report", "study_group": "PMID16352683", "access_depth": "abstract_metadata", "consensus_aspect": "CJC-1295 trial design, endpoints and access depth", "result_comparison": "Consensus correctly identified two blinded placebo-controlled ascending-dose trials and GH/IGF-I outcomes. Its own grounding snippets are labeled Abstract, despite a broader claim of Methods/Results validation. The original abstract confirms hormone activity and short tolerability, not clinical recovery; no original full-body access is asserted for this paper.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/16352683/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-0-10-10000.json" ], "body_receipts": [] }, { "pmid": "25331030", "doi": "10.1007/s00384-014-2030-8", "source_type": "primary study report", "study_group": "PMID25331030", "access_depth": "abstract_metadata", "consensus_aspect": "Ipamorelin clinical endpoint and translational boundary", "result_comparison": "Consensus correctly reports a primary-null postoperative-ileus trial. The original randomized report gives meal-tolerance medians of 25.3 and 32.6 hours with p=0.15 and no significant key or secondary efficacy differences. This tests intravenous single-agent postoperative care, not the healthy-adult CJC-ipamorelin stack. Nonsignificance is not equivalence.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/25331030/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-0-10-10000.json" ], "body_receipts": [] }, { "pmid": "19386527", "doi": "10.1016/j.ghir.2009.03.001", "source_type": "primary study report", "study_group": "CJC-pulsatility-cohort", "access_depth": "full_text_partial", "consensus_aspect": "CJC report overlap and biomarkers", "result_comparison": "Original Methods explicitly identify eleven men as a subset of a previously described cohort and repeat prior GH/IGF-I measurement procedures. The later serum-proteomic Results add candidate markers and correlations, not an independent clinical recovery experiment. Counts therefore group this report with the CJC pulsatility cohort rather than treating it as a new causal line.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/19386527/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-30-40-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\19386527-s1-p0-1-13.json", "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\19386527-s2-p2-3-4.json" ] }, { "pmid": "18981485", "doi": "10.7326/0003-4819-149-9-200811040-00003", "source_type": "primary study report", "study_group": "PMID18981485", "access_depth": "full_text_partial", "consensus_aspect": "GH-axis body composition versus function and power", "result_comparison": "The original MK-677 Methods define blinded randomized treatment and function tests including walking, stairs and chair rise, with primary power for fat-free mass and visceral fat. Original Results show GH/IGF-I and mass changes, no significant function change, and worsened glycemic measures. This independently strengthens the provider-described biomarker/function boundary while retaining the limitation that functional nulls were not adequately powered equivalence tests.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/18981485/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-50-51-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\18981485-s1-p0-1-10-11-18-19.json", "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\18981485-s2-p4-5-15-16-20-21.json" ] }, { "pmid": "25038357", "doi": "10.1001/jama.2014.8334", "source_type": "primary study report", "study_group": "NCT01263717", "access_depth": "full_text_partial", "consensus_aspect": "Tesamorelin indication and original endpoint hierarchy", "result_comparison": "Consensus used this trial as a rigorous indication-specific comparator. Original Methods verify HIV-related abdominal adiposity enrollment, blinded treatment, CT/MRS and metabolic monitoring; Results confirm visceral/liver-fat reduction and transient glucose or insulin-sensitivity signals. These endpoints do not demonstrate healthy-adult recovery or establish the net benefit of another secretagogue combination.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/25038357/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-10-20-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\25038357-s1-p1-2-4-6.json", "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\25038357-s2-p3-4-5-12.json" ] }, { "pmid": "42542926", "doi": "10.52312/jdrs.2026.2951", "source_type": "primary study report", "study_group": "PMID42542926", "access_depth": "abstract_metadata", "consensus_aspect": "Latest component-dismantling animal result", "result_comparison": "The provider summary relies heavily on reviews for healing-peptide boundaries. The examined 2026 original adds a four-arm thirty-two-rat Achilles-repair experiment: TB-500 alone showed significant mechanical benefit, and BPC-157 plus TB-500 did not add benefit over components. It strengthens the need for direct combination testing while preserving species, surgical-model and molecular-identity limits; it does not test CJC-ipamorelin.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42542926/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-40-51-10000.json" ], "body_receipts": [] }, { "pmid": "21204297", "doi": "10.1002/dta.233", "source_type": "primary study report", "study_group": "PMID21204297", "access_depth": "abstract_metadata", "consensus_aspect": "Commercial label versus clinical formulation identity", "result_comparison": "Consensus highlights the DAC versus similarly named marketed formulation boundary. The original analytical report identifies a twenty-nine-amino-acid peptide in an unknown product marketed as CJC-1295. Identity in that sample does not establish equivalence to the albumin-binding clinical formulation or market-wide safety and purity.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/21204297/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-30-40-10000.json" ], "body_receipts": [] }, { "pmid": "10496658", "doi": "10.1023/a:1018955126402", "source_type": "primary study report", "study_group": "PMID10496658", "access_depth": "abstract_metadata", "consensus_aspect": "Human ipamorelin target engagement", "result_comparison": "Original human dose-escalation PK/PD confirms a GH episode after intravenous ipamorelin. This supports the biological rationale retained in the review, but it is neither an injected-combination clinical efficacy trial nor a chronic recovery-safety test. Provider included counts and research-gap matrix cells are not used as numbers of direct human efficacy trials.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/10496658/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-0-10-10000.json" ], "body_receipts": [] }, { "pmid": "20439575", "doi": "10.7326/0003-4819-152-9-201005040-00007", "source_type": "primary study report", "study_group": "PMID20439575", "access_depth": "abstract_metadata", "consensus_aspect": "Positive sprint result and fluid interpretation", "result_comparison": "Consensus correctly notes a short-lived sprint effect and extracellular-water-driven lean-mass gain. The original blinded 96-athlete trial reports a 3.9 percent GH-associated sprint increase, no significant other performance changes and loss of the sprint effect after washout. This positive is retained rather than cherry-picking only null GH comparators; it is a different hormone exposure and endpoint from exact-stack recovery.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/20439575/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-51-56-10000.json" ], "body_receipts": [] }, { "pmid": "10477776", "doi": "10.1056/NEJM199909093411102", "source_type": "primary study report", "study_group": "PMID10477776", "access_depth": "abstract_metadata", "consensus_aspect": "Critical-illness safety boundary", "result_comparison": "The original two randomized high-dose GH trials show increased mortality in prolonged critical illness. This serious harm must remain bounded to its measured population and exposure; it cannot become an asserted CJC-ipamorelin mortality rate in healthy adults.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/10477776/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-51-56-10000.json" ], "body_receipts": [] } ], "grade_changed": false, "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.", "raw_receipts": [ { "path": "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\consensus-provider-checkpoint-1551-private.json", "sha256": "dd476771ded70863f0c0690e923bf411f3951dad26c55463e8bf4a03f3ebd5cd" } ], "independent_blinded_audit": false, "cutoff": "2026-10-13", "completed_utc": "2026-10-13T16:38:31.829865+00:00", "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them." } }